Proteome-wide Identification of New Molecular Targets Affected by Methotrexate in Acute Promyelocytic Leukaemia Cell Line by Agarwal, Nitin Kumar
 
 
Proteome-wide Identification of New Molecular Targets 
Affected by Methotrexate in Acute Promyelocytic 






zur Erlangung des Doktorgrades 
der Mathematisch-Naturwissenschaftlichen Fakultäten 






Nitin Kumar Agarwal 





























Referent: Prof. Dr. R. Hardeland 
Korreferent: Prof. Dr. D. Doenecke 
Tag der mündlichen Prüfung: May 02, 2007 
ABSTRACT 
 i
Proteome-wide Identification of New Molecular Targets 
Affected by Methotrexate in Acute Promyelocytic  
Leukaemia Cell Line 
 
Nitin Kumar Agarwal 
Georg-August-Universität zu Göttingen, 2007 
 
ABSTRACT 
Methotrexate (MTX) was first introduced as a cytotoxic agent that inhibits nucleotide 
biosynthesis in various cancer disorders. Accumulating evidences suggest that MTX 
inhibits the proliferation of malignant cells by inhibiting 5-aminoimidazole-4-carbox-
amide ribonucleotide transformylase, isoprenylcysteine carboxyl methyltransferase and 
NF-κB transcription factor. These observations indicate that MTX could have additional 
molecular targets that are therefore unappreciated. To get insights into the complex 
molecular mechanisms of MTX induced apoptosis in acute promyelocytic leukemia cells 
(HL-60), we conducted an investigation incorporating cysteine labeled differential in-gel 
electrophoresis combined with mass spectrometry. Initial experimental analysis revealed 
that 24 proteins were differentially expressed (p < 0.05) in HL-60 cell proteome after 
addition of 2.5 µM MTX for 72 h. The majority of MTX induced proteins were ascribed 
to the endoplasmic reticulum (ER) chaperones, glycolytic enzymes and the mitochondrial 
transmembrane electron transport system (MTETS). In particular, we noted that three 
structural α4, α5, α7; a non-catalytically β3 and two 26S regulatory proteasome subunits 
were significantly down regulated in MTX treated HL-60 cell. We further showed in 
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HL-60 cells that MTX induces ER chaperones, suppresses the NF-κB subunit p65, 
disturbs the mitochondrial transmembrane potential (∆ψm) and generates reactive oxygen 
species (ROS) in a time-dependent manner. All together, our findings revealed that MTX 
alter the level of a variety of proteins involved in the NF-κB associated proteasome 
complex formation, ER stress, and the MTETS. Their identification as molecular targets 
of MTX may provide new impulse in the understanding of apoptotic activities in acute 




TABLE OF CONTENTS 
1 INTRODUCTION.................................................................................................... 1 
1.1 THE MOLECULAR BASIS OF LEUKAEMIAS .................................................. 1 
1.1.1 Differentiation blockade: The role of transcription factors in APL ............ 2 
1.1.2 Core binding factors in APL........................................................................ 2 
1.1.3 Molecular deregulation of receptor tyrosine kinases in APL ...................... 3 
1.1.4 The BCR-ABL fusion gene and leukaemia ................................................. 4 
1.1.5 Activated mutation in Fms-like tyrosine kinase-3 receptor......................... 4 
1.1.6 Inappropriate proliferation: The role of signalling molecules..................... 5 
1.1.7 Escape from apoptosis ................................................................................. 7 
1.2 CURRENT THERAPIES AND FUTURE DIRECTIONS..................................... 7 
1.3 ANTI-METABOLITES (FOLIC ACID ANALOGUES)........................................ 8 
1.3.1 History of MTX ........................................................................................... 8 
1.3.2 Chemistry and metabolic activities of folates.............................................. 9 
1.3.3 Mechanism of action of MTX ................................................................... 12 
2 AIM OF THE STUDY ........................................................................................... 14 
3 MATERIALS.......................................................................................................... 15 
3.1 REAGENTS........................................................................................................ 15 
3.2 CELL LINES ...................................................................................................... 15 
3.2.1 HL-60 cell line (Human promyelocytic leukaemia cell) ........................... 15 
3.2.2 A498 cell line (Renal epithelial carcinoma cell) ....................................... 16 
3.3 BUFFERS AND SOLUTIONS ........................................................................... 17 
3.4 EQUIPMENTS................................................................................................... 18 
3.5 SCIENTIFIC ONLINE SEQUENCES AND SOFTWARE SERVICES............... 19 
4 EXPERIMENTAL PROCEDURES..................................................................... 20 
4.1 CELL CULTURE PROCEDURES .................................................................... 20 
4.2 CELL VIABILITY ASSAY................................................................................... 20 
4.3 DETECTION OF PHOSPHATIDYLSERINE BY ANNEXIN-V......................... 20 
 
 II
4.4  CELL LYSATE PREPARATION FOR TWO DIMENSIONAL GEL 
ELECTROPHORESIS........................................................................................ 21 
4.5 PROTEIN PRECIPITATION AND ESTIMATION ............................................ 21 
4.6 PROTEIN CYDYES SATURATION LABELLING............................................. 22 
4.7 TWO DIMENSIONAL GEL ELECTROPHORESIS .......................................... 25 
4.8 PROTEIN VISUALIZATION AND IMAGE ANALYSIS..................................... 26 
4.9 IN-GEL DIGESTION AND MALDI-TOF MS ANALYSIS OF PROTEIN SPOTS
 27 
4.10 PEPTIDE SEQUENCE ANALYSIS ................................................................... 27 
4.11 DATABASE SEARCH AND PROTEIN IDENTIFICATION.............................. 28 
4.12 WESTERN BLOT ANALYSIS............................................................................. 29 
4.13 PYRUVATE KINASE ACTIVITY ASSAY ........................................................... 30 
4.14 ANALYSIS OF MITOCHONDRIA MEMBRANES POTENTIAL ...................... 30 
4.15 DETECTION OF ROS....................................................................................... 31 
4.16 STATISTICAL DATA ANALYSIS....................................................................... 32 
5 RESULTS................................................................................................................ 33 
5.1 MTX DEMONSTRATES CELL TOXICITY ON HL-60 CELLS......................... 33 
5.2 MTX INDUCES APOPTOSIS IN HL-60 AND A498 CELLS ............................ 34 
5.3 EVALUATING EXPERIMENTAL REPRODUCIBILITY OF THE CYSTEINE 
LABELLED IN-GEL ELECTROPHORESIS APPROACH................................ 39 
5.4  IDENTIFICATION OF DIFFERENTIALLY EXPRESSED PROTEINS IN MTX 
TREATED HL-60 CELLS .................................................................................. 42 
5.4.1 MTX down regulates proteasome subunits in HL-60 cells ....................... 48 
5.4.2 Differential effect of MTX on glycolytic and MTETS pathways ............. 51 
5.5  MTX INDUCES ER STRESS IS LINKED TO ALTERATION IN THE 
PROTEASOME PROTEIN EXPRESSION ........................................................ 54 
5.6  MTX ALTERS MITOCHONDRIAL MEMBRANE POTENTIAL AND 
GENERATES ROS............................................................................................. 57 
 
 III
6 DISCUSSION ......................................................................................................... 61 
6.1  SEQUENTIAL EVENTS OF APOPTOSIS INDUCED IN MTX TREATED 
CANCER CELLS ............................................................................................... 61 
6.2  MOLECULAR TARGETS AND PATHWAYS INVOLVED IN CELL RESPONSE 
TO MTX ............................................................................................................. 63 
6.2.1 MTX induced inhibition of NF-κB subunit p65 and proteasome subunits 
correlate with the induction of ER chaperones.......................................... 64 
6.2.2 MTX induced MTETS proteins impairment reveal glycolysis involvement
 66 
7 CONCLUSION....................................................................................................... 69 
8 APPENDIX ............................................................................................................. 70 
9 BIBLIOGRAPHY .................................................................................................. 95 
10 ACKNOWLEDGEMENT................................................................................... 107 
 
 IV
LIST OF FIGURES 
Figure 1.   The chemical structure of pteroylglutamic acid (folic acid) .............................. 9 
Figure 2.   Folate in nucleic acid metabolism.................................................................... 11 
Figure 3.   Sites of action of MTX and MTX polyglutamates........................................... 13 
Figure 4.   Schematic diagram of labelling reaction of protein thiols with maleimide 
CyDyes ............................................................................................................ 23 
Figure 5.   Workflow for cysteine labelled differential in-gel electrophoresis analysis.... 24 
Figure 6.   Impact of MTX on HL-60 cells........................................................................ 34 
Figure 7.   Morphological changes observed in HL-60 cells after MTX treatment .......... 35 
Figure 8.   Assessment of apoptosis by FITC-labelled-annexin-V staining assay ............ 37 
Figure 9.   Morphological events of apoptosis examined by flow cytometry ................... 38 
Figure 10.  Partial view of two-dimensional gel electrophoresis; gels obtained from  MTX 
treated HL-60 cell lysates visualised by silver stain or Cy5 dye..................... 40 
Figure 11.  Evaluation of experimental reproducibility by Scatter Plot analysis .............. 41 
Figure 12.  Large dual colour two-dimensional image of proteins expression profile 
obtained from untreated and MTX treated HL-60 cell lysates labelled with 
corresponding CyDyes..................................................................................... 44 
Figure 13.  Down regulation of six proteasome subunits in MTX treated HL-60 cells .... 50 
Figure 14.  MTX induces pyruvate kinase activity and increases the expression of 
triosephosphate isomerase (TPI) in HL-60 and A498 cancer cells ................. 52 
Figure 15.  Differential expression of mitochondrial proteins in MTX treated HL-60 cell 
line ................................................................................................................... 54 
Figure 16.  Western blot analyses of ER chaperones and NF-κB affected by MTX in 
HL-60 and A498 cancer cells .......................................................................... 56 
Figure 17   MTX induces apoptosis is associated with altered mitochondrial membrane 
potential ........................................................................................................... 58 
Figure 18.  Induction of ROS formation in MTX treated A498 cells................................ 60 
 
 V
LIST OF TABLES 
Table 1.   Multisteps protocol for isoelectric focusing of IPG strips................................. 25 
Table 2.   Excitation and emission wavelengths used for imaging of fluorochrome labelled 
gels................................................................................................................... 26 
Table 3.   Summary of untreated and MTX treated HL-60 proteome analysed by Delta 2D 
software ........................................................................................................... 45 
Table 4.   List of the proteins that were differentially expressed in HL-60 cells during 
treatment with 2.5 µM MTX for 72 hours....................................................... 46 
Table 5.   Over expression of glycolytic enzymes in MTX treated HL-60 cells............... 51 
LIST OF ABBREVIATIONS 
 I
LIST OF ABBREVIATIONS 
Abbreviation Denotation 
A498 Renal carcinoma cell line 
ACN Acetonitrile 
ADP Adenosine diphosphate 
AICAR 5-aminoimidazole-4-carboxamide ribonucleotide transformylase 
APL Acute promyelocytic leukaemia 
APS Ammonium persulfate 
CHAPS 3-(3-cholamidopropyl)-dimethylammoniopropane sulfonate 
CyDyes Cyanine dyes 
DHFR Dihydrofolate reductase 
DH-123 Dihydrorhodamine 
DMF Dimethylformamide 
DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic acid 
ER Endoplasmic reticulum 
FCS Fetal calf serum 
FLT3 Fms-like tyrosine kinase 3 
H2O2 Hydrogen peroxide 
HL-60 Acute promyelocytic leukaemia cell line 
HRP Horseradish peroxidase 
IC60 Inhibition concentration (60 %) 
ICMT Isoprenylcysteine carboxyl methyltransferase 
IEF Isoelectric focusing 
IPG Immobilized pH gradient strip 
ITDs Internal tandem duplications 
kDa Kilodalton 
MTETS Mitochondrial transmembrane electron transport system 
MTX Methotrexate 
NaCI Sodium chloride 
LIST OF ABBREVIATIONS 
 II
NADH Nicotinamide adenine dinucleotide; reduced form 
NF-κB Nuclear factor-kappa B 
NP-40 Nonylphenyl polyethylene glycol 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffer saline 
PI3K Phosphoinositide-3-kinase 
PLZF Promyelocytic leukaemia zinc finger protein 
PMSF Phenylmethanesulfonyl fluoride 
PtdSer Phosphatidylserine 
PteGlu Pteroylglutamic acid 
RTKs Receptor tyrosine kinases 
SadoMet S-adenosylmethionine 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SV40 Simian virus 40 
TCEP Tris (2-carboxyethyl) phosphine hydrochloride 
TEMED N,N,N’,N’-Tetramethylethylenediamine 
TFA Trifluoracetic acid 
Tris Tris (hydroxymethyl) aminomethane 
Tween Polyoxyethylene (80) sorbitan monolaurate 




Leukaemias are malignant neoplasms of haematopoietic cells. They can be acute or 
chronic. The acute leukaemias are a heterogeneous group of neoplasm arising from 
transformation of uncommitted or partially committed haematopoietic stem cells. Acute 
leukaemias are in general divided into myeloid and lymphoid leukaemia. They differ not 
only in their clinical presentation but also substantially in response to therapy and 
following course. Although the French-American-British (FAB) morphologic 
classification of acute promyelocytic leukaemia (APL) vs. acute lymphoblastic leukaemia 
(ALL) has been accepted for many years (Leymarie et al., 2004), the important advances 
in cytogenetic, immunophenotype and genetic fields needed to be integrated in an updated 
approach to classify leukaemias. 
The recognition of distinctive morphologies that correlate with the specific chromosomal 
translocation and development of treatments are based on specific genetic defects (Lopez-
Terrada, 2006). Molecular genetic analysis of acute leukaemia has been at the forefront of 
research into the pathogenesis of cancer because the presence of recurring chromosomal 
translocations provides immediate clues to the genetic events and identifies the 
deregulated oncogenes leading to leukaemias (Ikeda et al., 2006). 
1.1 THE MOLECULAR BASIS OF LEUKAEMIAS 
Leukaemias are characterized by acquisition of recurring genetic aberrations. Important 
insights into the molecular basis of leukaemias have been obtained by inhibition of 
differentiation, deregulation of tyrosine kinases, and inappropriate proliferation in the 
absence of normal growth signals finally lead to cell death (Cline, 1994). These factors 
are often not sufficient to cause leukaemia and appear to be a part of the complex 
signalling network. Hence, understanding the impaired genes complex and related 
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aberrant oncogenic cell signalling proteins have paved the way for new treatment 
modalities that target specific gene products implicated in cancer. 
1.1.1 Differentiation blockade: The role of transcription factors in APL 
The most common targets of leukaemia-associated chromosomal translocations are genes 
that encode DNA-binding transcription factors or regulatory component of transcriptional 
complexes (Look, 1997). A number of recurrent chromosomal translocations have been 
cloned and characterized in specific subtypes of leukaemia. For example, t(15;17) is 
mainly found in APL patients (Chou and Dang, 2005), whereas t(1;19) is basically 
involved in B-cell precursor ALL patients (Hunger, 1996). 
Chromosomal translocations in APL can be broadly grouped into Hox family members, 
ETS family members, Core binding factors, and other transcriptional regulatory proteins. 
The most common translocation in APL is the fusion of the retinoic acid receptor-α chain 
either to the PML gene (PML-RARα) or to the promyelocytic leukaemia zinc finger 
protein (PLZF / RARα) (Chen et al., 1993). Transformation in each of these cases 
proceeds the generation of fusion protein that interferes in a dominant manner with the 
function of the wild type protein. This chromosomal rearrangements result in abnormal 
proliferation, lack of differentiation, and disruption of apoptosis thereby giving the 
leukaemia cells an advantage to expand abnormally in various in-vivo and in-vitro 
experimental models (Van Etten and Shannon, 2004). 
1.1.2 Core binding factors in APL 
Genes that constitute the core binding factors are essential for haematopoiesis. Cloning of 
the AML-associated t(8;21) translocation led to the identification of AML1. It encodes 
DNA-binding subunit of AML1-CBFβ, a transcription factor that regulates a number of 
haematopoiesis specific genes and is essential for the development of haematopoietic cell 
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system (Wang et al., 1996). Fusion gene products formed by t(8;21) translocation joins 
the N-terminal part of AML1 including the DNA-binding and CBFβ interaction domains, 
with the C-terminal portion of the 8;21 gene  (ETO) on chromosome 8 (Yergeau et al., 
1997). The resultant complex retains its ability to bind AML1-regulated target sequences 
and represses AML1-mediated transcription (Liu et al., 1993). Further evidences suggest 
that ETO's ability to repress transcription is mediated by its interaction with nuclear 
receptor corepressor (N-CoR) and recruitment of N-CoR / Sin3 / HDAC1 complex in the 
nucleus (Wang et al., 1998). By permanently tethering this repressive complex to 
AML1-responsive promoters, AML1-ETO actively suppresses transcription by 
maintaining the histones in a deacetylated conformation and making DNA inaccessible to 
the transcriptional apparatus. Hence, inhibition of AML1-responsive gene probably block 
myeloid development and leukaemic transformation in maturing haematopoietic 
progenitors (Wang et al., 1998). 
1.1.3 Molecular deregulation of receptor tyrosine kinases in APL 
Receptor tyrosine kinases (RTKs) are transmembrane proteins having ligand binding 
extra cellular domain and a catalytic intracellular kinase domain. In the absence of 
ligands, RTKs are monomeric, unphosphorylated and kinase domains are inactive. 
Binding of ligand to the extra cellular domain results in receptor oligomerization and 
autophosphorylation of the tyrosine residue within the activation loop of the kinase. Upon 
tyrosine phosphorylation, other signalling proteins are recruited to the membrane and 
intracellar signal cascade is activated (Ikeda et al., 2006). A common mechanism in 
leukaemias is the fusion of a receptor tyrosine kinase with a partner protein as a result of 
chromosomal translocation, e.g., BCR-ABL (Perrotti and Calabretta, 2004). 
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1.1.4 The BCR-ABL fusion gene and leukaemia 
Chronic promyelocytic leukaemia is a clonal stem cell disorder, which is characterized by 
a t(9;22)(q34;q11) chromosomal translocation known as the Philadelphia chromosome 
(Sawyers, 1992). This classical translocation in leukaemia cells occurs by the fusion of 
two genes, BCR and ABL results in a formation of fused gene known as BCR-ABL. The 
fusion product is generally expressed as chimeric protein of 210 kDa molecular weight 
(also known as p210) (Perrotti and Calabretta, 2004). p210 is over expressed in freshly 
isolated cells derived from patients with chronic promyelocytic leukaemia and contain 
tyrosine kinase activity (Lim et al., 1999). In addition to this, leukaemic cells expressing 
BCR-ABL are also protected from apoptosis by preventing cytosolic accumulation of 
cytochrome-c and inhibition of caspase 3 (Bedi et al., 1995; Bedi et al., 1994). Moreover, 
activation of Ras G proteins are required for transformation by ABL oncogenes, activate 
several signalling pathways such as the RAS signalling pathway, the JNK and STAT 
pathways as well as the phosphatidyl inositol-3-kinase pathway (Daley et al., 1990). 
Ras-GTP also contributes to the PI3-kinase pathway activation by binding a site within 
class I catalytic subunits (Rodriguez-Viciana et al., 1994). 
1.1.5 Activated mutation in Fms-like tyrosine kinase-3 receptor 
Fms-like tyrosine kinase-3 (FLT3) is a tyrosine kinase receptor, involved in stem cell 
proliferation, increase invasiveness, angiogenesis and metastasis (Krause and Van Etten, 
2005). FLT3 is a most common mutated gene in APL and is constitutively activated by 
acquired mutation in approximately 12-42 % of APL patients (Thiede et al., 2002). Two 
types of mutations have been attributed to the deregulated FLT3 receptor. Firstly, in most 
cases of APL, there are internal tandem duplication (ITD) mutations in the 
juxtamembrane domain of FLT3, ranging in size from several to > 50 amino acids 
(Grundler et al., 2005). These mutations are always in frame and the diversity of 
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mutations among patients has suggested that there may be the loss-of-function mutations 
in an auto inhibitory domain. ITD mutations occur exclusively within 27–amino acids 
stretch and lead to structural inactivation of the tyrosine kinase. Clinical studies identify 
ITD mutations in 17-26 % of APL cases (Moreno et al., 2003). 
Secondly, a small percentage of APL mutations occur in the activation loop of FLT3 
resulting in constitutive kinase activation. The most common activating point mutation is 
the substitution of tyrosine for aspartic acid at position 835 within the activation loop of 
the kinase domain (Yamamoto et al., 2001). Point mutations at other positions, such as 
836 and 841 have also been associated with FLT3 independent activation of tyrosine 
kinase activity (Thiede et al., 2002). The FLT3-D835 mutation is observed in 7 % of APL 
cases (Murphy et al., 2003; Levis and Small, 2003). Thus, FLT3 appears to be necessary 
for disease progression in APL and is therefore a potential target for leukaemic therapy. 
1.1.6 Inappropriate proliferation: The role of signalling molecules 
It has been proved in leukaemias that activation of specific genetic programs that are 
coordinated by signal transduction pathways of growth factor and cytokine stimulation 
can determine cell division, apoptosis, or differentiation. The RAS signalling pathway is 
mainly activated by a spectrum of haematopoietic cytokine receptors in response to ligand 
stimulation and play an important role in the proliferation of haematopoietic progenitors 
(Bartek and Lukas, 2001). Members of the RAS gene family (K-RAS, N-RAS and 
H-RAS) are key oncogene homolog, involved in a number of signal transduction 
pathways. Oncogenic N-RAS and K-RAS mutations are generally found in approximately 
25 % in APL, 30 % in myeloma and 6-20 % in ALL patients (Padua et al., 1998). These 
mutations frequently involve single amino acid substitution at codons 12, 13, or 61 in the 
GTP binding site that abrogate intrinsic RAS GTPase activity and lead to constitutive 
RAS activation (Neri et al., 1988; Gougopoulou et al., 1996). 
INTRODCUTION 
 6
RAS oncogenic proteins undergo a complex series of posttranslational modifications 
before they are fully functional. These modifications occur at the C-terminal CAAX motif 
and are initiated by the addition of an isoprenoid lipid through a process known as 
prenylation (Hancock et al., 1989). Following prenylation, these proteins usually undergo 
endoproteolytic processing by RCE1 protease and then carboxyl methylation by a unique 
methyltransferase known as isoprenylcysteine carboxyl methyltransferase (ICMT) 
(Winter-Vann and Casey, 2005). Although inhibitors targeting the prenylation step are 
now in advanced-stage clinical trials, but their therapeutic utility and efficacy seems to be 
limited (Morgan et al., 2003). Recent findings indicate that the inhibition of the post-
prenylation processing steps, particularly ICMT catalysed methylation might provide a 
better approach to the control of cancer cell proliferation (Winter-Vann and Casey, 2005). 
NF-κB (Nuclear factor-kappa B) signalling pathway is also commonly found in all 
haematopoietic cell types and involved in haematopoietic cell survival (Pyatt et al., 1999), 
erythropoiesis (Zhang et al., 1998), neutrophil activation (McDonald et al., 1997); B-cell 
and T-cell development (Grumont et al., 1998). Abnormalities in the NF-κB regulation 
has been associated with the development of human lymphomas (Neri et al., 1991). 
Furthermore, a number of reports have shown that activation of NF-κB is critical for the 
pathogenesis of leukaemias (Baumgartner et al., 2002; Braun et al., 2006; Bueso-Ramos 
et al., 2004; Guzman et al., 2001). 
It had already been shown that human leukaemic cells expressed abnormally high level of 
proteasomes as compared to normal peripheral blood cells (Kumatori et al., 1990) 
Therefore, it seems to be reasonable that proteasome inhibitors initiate apoptosis in 
leukaemic cells. While proteasome inhibitors function through multiple pathways, the 
most important one is the blocking of the survival signals regulated by NF-κB (Adams, 
2004). This observation is consistent with studies in many cancer types, indicating a 
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central role of NF-κB in promoting tumour growth and survival of cancer patients (Karin, 
2006). 
1.1.7 Escape from apoptosis 
In normal haematopoiesis, there is a fine balance between proliferation and apoptosis, 
reflecting coordination between pro and anti-apoptotic genes (Schulte-Hermann et al., 
1999). In cancer cells, this delicate balance is disrupted by a number of mutations result in 
increasing the anti-apoptotic gene expression and thereby shifting this balance in favour 
of proliferation. BCL-2 is a proto-oncogene that was originally cloned from a follicular 
lymphoma t(14;18) translocation (Tsujimoto et al., 1985). It encodes mainly 
mitochondrial protein and promotes cell survival by blocking the release of cytochrome-c 
thus preventing caspase activation (Rosse et al., 1998). BCL-2 also suppresses p53 and 
c-Myc dependent apoptosis (Sachs and Lotem, 1993). Small interfering RNA against 
BCL-2 has been found to be effective in primary APL cells (Reed, 2003). 
1.2 CURRENT THERAPIES AND FUTURE DIRECTIONS 
Initially, the combination chemotherapy for APL has consisted of induction with 
cytarabine (Ara-C) and anthracycline followed by consolidation with Ara-C (Stone, 
2002). While this approach achieves remission for a majority of APL patients, relapse is 
common and long-term survival rates remain low. Recent experimental evidences indicate 
that both Ara-C and anthracycline are less effective in primitive APL cells as compared to 
leukaemic blasts (Costello et al., 2000; Guzman et al., 2001). Therefore, targeted therapy 
is a frontline treatment for haematological malignancies and became the novel treatment 
modalities for leukaemia patients. The differential clinical outcomes associated with the 
APL can be attributed primarily to drug sensitivity or resistance of promyelocytic cells 
harbouring specific genetic abnormalities (Daley et al., 1990; Pyatt et al., 1999; Thiede et 
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al., 2002; Wang et al., 1998; Wang et al., 1996). Although the mechanism of leukaemic 
transformation is not precisely known, patients with this abnormality have a favourable 
prognosis when they are treated with folate analogues based regimens (Rots et al., 2001; 
Goker et al., 1995). The unique sensitivity of leukaemic cells to MTX correlates with their 
propensity to undergo spontaneous apoptosis when cultured in vitro and to have higher-
than-average intracellular concentrations of MTX and its active polyglutamate after in 
vivo treatment (Rots et al., 2001). 
1.3 ANTI-METABOLITES (FOLIC ACID ANALOGUES) 
Dihyrofolate reductase (DHFR) is a primary site of action for most folate analogues. 
Inhibition of DHFR leads to toxic effects through partial depletion of tetrahydrofolate 
(FH4) cofactors that are required for the purine and thymidylate synthesis (Genestier et 
al., 2000). Various chemotherapeutic agents have been identified having weak affinity 
with human DHFR and strong activity against bacterial and parasitic infections. By 
contrast, MTX is an effective inhibitor of DHFR in all species. Crystallographic and 
oligonucleotide-directed mutagenesis studies explained high affinity and species 
specificity of MTX with DHFR (Blakley and Sorrentino, 1998; Matthews et al., 1985; 
Schweitzer et al., 1989; Stone and Morrison, 1986). 
1.3.1 History of MTX 
MTX, a folate analogue, first synthesized by Sidney Farber in collaboration with Harriett 
Kilte and Lederle chemists. It was the first example of rational drug design developed for 
the treatment of ALL (Farber, 1950). It was further reported to cure choriocarcinoma 
(Berlin et al., 1963). The consistent cure of choriocarcinoma by MTX provided great 
impetus to investigations into the chemotherapy of cancer. Besides its anticancer activity, 
MTX is widely used in the treatment of psoriasis, rheumatoid arthritis (Takimoto and 
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Allegra, 1995) primary biliary cirrhosis, Crohn’s disease, and intrinsic asthma (Genestier 
et al., 2000). 
1.3.2 Chemistry and metabolic activities of folates 
The structural formula of pteroylglutamic acid (PteGlu) is shown in Figure 1. Major part 
of the molecule includes pteridine ring linked by a methylene bridge to paraminobenzoic 
acid, which is joined by an amide linkage to glutamic acid. While PteGlu is the common 
pharmaceutical form of folic acid, it is neither the principle folic acid congener in food 
nor the active coenzyme for intracellular metabolism. Following absorption PteGlu is 
rapidly reduced to dihydrofolate (FH2) and subsequently to tetrahydrofolate (FH4). Both 





Figure 1. The chemical structure of pteroylglutamic acid (folic acid) 
In the form of a series of FH4 compounds, folate accepts one-carbon units from donor 
molecule and plays a specific role in the intracellular metabolism (Choi and Mason, 2000) 




A. Utilization or generation of formate. This reversible reaction utilizes FH4 and 
10-methyltetrahydrofolate (CH3FH4). 
B. Conversion of serine to glycine. This reaction requires FH4 as an acceptor of a 
methylene group from serine and utilizes pyridoxal phosphate as a cofactor 
resulting in the formation of 5, 10-methylenetetrahydrofolate (CH2FH4), an 
essential coenzyme for thymidylate synthesis. 
C. Histidine metabolism. FH4 also acts as an acceptor of a formimino group in the 
conversion of formiminoglutamic acid to glutamic acid. 
D. Conversion of homocysteine to methionine. Methionine is regenerated from 
homocysteine in a reaction catalysed by an enzyme known as CH3FH4 
homocysteine methyltransferase. This reaction requires CH3FH4 as a methyl donor 
and utilizes vitamin B12 as a cofactor. Further, methionine is converted into 
S-adenosylmethionine (SAM) in a reaction catalysed by methionine adenosyl 
transferase. SAM then donates the labile methyl group for over than 80 biological 
methylation reactions, including an array of reactions whereby specific sites 
within DNA and RNA become methylated (Figure 2). 
E. Nucleic acid metabolism. The synthesis and turnover of deoxynucleoside 
triphosphate (dNTP) pools are tightly coupled to DNA synthesis. dNTPs are the 
immediate source of substrates for the polymerase reactions involved in DNA 
replication. Therefore, deoxynucleotides are critical for DNA synthesis. Folate 
derived one–carbon groups are essential for the de novo synthesis of the 
thymidylate and the purines. 
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• Synthesis of thymidylate. CH2FH4 donates a methylene group and reducing 
equivalents to deoxyuridylate for the synthesis of thymidylate, a rate-
limiting step in DNA synthesis. 
• (b) Synthesis of purine. Two steps in the synthesis of purine nucleotides 
require the participation of derivatives of folic acid. Glycinamide 
ribonucleotide is formylated by 5, 10-methenyltetrahydrofolate (CHFH4); 




Figure 2. Folate in nucleic acid metabolism 
FH4, tetrahydrofolate; FH2, dihydrofolate; SAM, S-adenosylmethionine; SAH, 
S-adenosylhomocysteine; (1) methyltetrahydrofolate homocysteine methyltransferase; 
(2) methionine adenosyl transferase; (3) methylenetetrahydrofolate reductase (Adapted 
from Choi and Mason, 2000) 
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1.3.3 Mechanism of action of MTX 
MTX is a potent inhibitor of DHFR (Ki ≈0.01 to 0.2 nM), prevents the formation of FH4, 
producing an intracellular deficiency of certain folate coenzymes leading to accumulation 
of the toxic inhibitory substrate known as polyglutamate (Figure 3). However, it has been 
noted in some experimental models that the inhibition of folic acid metabolism could not 
be completely responsible for the antiproliferative effect of MTX (Sant et al., 1992). The 
one-carbon transfer reactions play a crucial role in the de novo synthesis of purine 
nucleotides and thymidylate synthesis with the subsequent interruption of the DNA and 
RNA synthesis (Allegra et al., 1985) as depicted in Figure 2. A number of other 
important observations have been made which point towards the additional molecular 
influences of MTX such as inhibition of the ICMT (Winter-Vann et al., 2003) and 
suppression of the NF-κB subunits p65 and p50. The suppression of the NF-κB was 
accompanied by inhibition of IKBα phosphorylation and degradation (Majumdar and 
Aggarwal, 2001). Nevertheless, the molecular targets and their underlying pathways that 






Figure 3. Sites of action of MTX and MTX polyglutamates 
MTX enters into the cells by either the reduced folate carrier (1) or the membrane folate 
binding protein (2). MTX is then polyglutamylated by the enzyme folylpolyglutamate 
synthetase (3). MTX (glu)n is a potent inhibitor of dihydrofolate reductase (DHFR) (4). 
MTX polyglutamates are hydrolyzed to MTX in the lysosome by g-glutamyl hydrolase 
(GGH) (5). CH2FH4 = 5,10-methylene tetrahydrofolate; dTMP = deoxythymidine 
monophosphate; dUMP = deoxyuridine monophosphate/deoxyuridylate; FH2 = 
dihydrofolate; FH4 = tetrahydrofolate; MTX = methotrexate; MTX (glu)n = methotrexate 
polyglutamate with n glutamate residues (Adapted from Cancer Medicine 6, 2003). 
 
AIM OF THE STUDY 
 14
2 AIM OF THE STUDY 
MTX was used to treat choriocarcinoma and trophoblastic cancers (Homesley et al., 
1988; Goldstein et al., 1976); cure rate was 90 % in early cases and 75 % in advance 
cases after exposure to MTX and dactinomycin. Beneficial effects were also observed in 
patients with osteosarcoma (Souhami et al., 1997) and mycosis fungoides (Groth et al., 
1979), when MTX was used as part of the combination therapy. High doses of MTX, with 
leucovorin rescue, can cause substantial tumour regression in Burkitt’s and 
non-Hodgkin’s lymphomas, and carcinomas of breast, head, neck (Frei, III et al., 1980). 
Recently, in many clinical trials MTX has been established as an effective treatment of 
leukaemias and other cancers (Levine et al., 2005; Winter et al., 2006; Whitehead et al., 
2005). 
Therefore, it is of utmost importance to understand the complete molecular mechanism of 
MTX in the treatment of cancer, particularly leukaemia. Towards this aim, the present 
study was design to identify the molecular targets and their underlying molecular 






L-glutamine, Penicillin, Streptomycin, MTX, DTT, and Iodoacetamide were purchased 
from Sigma-Aldrich Chemie GmbH, Steinheim, Germany. CHAPS [(3Cholamidopropyl) 
dimethyl-ammonio] –1-propanesulfonate] was obtained from Merck KGaA, Darmstadt, 
Germany. Precision plus protein marker was purchased from Bio-Rad Laboratories, CA, 
USA. Protease inhibitor Mix 100 was obtained from Amersham Biosciences GmbH, 
Freiburg, Germany. A Sequazym™ peptide Mass standard Kit was purchased from 
Applied Biosystems, CA, USA. 
3.2 CELL LINES 
HL-60 and A498 cell lines were obtained from DSMZ GmbH, Braunschweig, Germany 
and ATCC, Manassas, USA, respectively. Cell lines basic properties are briefly described 
as follow: 
3.2.1 HL-60 cell line (Human promyelocytic leukaemia cell) 
The HL-60 cell line, derived from an APL patient (Collins et al., 1977), proliferates 
continuously and consists predominantly of a neutrophilic promyelocyte with prominent 
nuclear / cytoplasmic asynchrony. These cells represent a transformed phenotype, form 
colonies in semisolid medium and produce subcutaneous myeloid tumours in nude mice. 
The morphological and histochemical karyotypic similarity; responsiveness to chemical 
induction of differentiation is essentially unchanged to the patient's leukaemic cells 
(Gallagher et al., 1979). Therefore, HL-60 cell line provides a continuous source of 
human cells for studying molecular events of APL proliferation and the effects of various 







3.2.2 A498 cell line (Renal epithelial carcinoma cell) 
 
ATCC Number   HTB-44 ™ 
 
Species    Homo sapiens 
 
Source     Kidney 
 
Disease    Renal cell carcinoma 
 
Growth properties   Adherent 
 
Morphology    Epithelial 
 
Tumorigenic Nude mice; forms undifferentiated carcinoma; also 







3.3 BUFFERS AND SOLUTIONS 
Following buffers and solutions are most frequently used in the Experimental Procedures. 
Others are cited in the text. 
 
Standard Culture Medium  DMEM and RPMI 
 10 % (v/v) FCS  
 1 % (v/v) L-Glutamine 
 1 % (v/v) Penicillin /Streptomycin 
  
Cell Lysis Buffer (2D gel electrophoresis) 9.5 M urea 
 2 % w/v CHAPS 
 2 % v/v ampholytes 
 1 % w/v DTT 
 10 mM PMSF adjust pH 7.5 with appropriate 
acid/base 
  
Electrophoresis Buffer (5x) 125 mM Tris 
 1 M Glycine 
 0.5 % w/v SDS  
  
Colloidal Coomassie staining solution 40 % v/v Methanol 
 40 % v/v Water 
 20 % v/v Coomassie solution 
  
Silver staining solutions  
  
Fixation solution 50 % v/v Methanol 
 12 % v/v Acetic acid 
 38 % v/v Water 
  
Wash solution I 50 % v/v Ethanol 
 50 % v/v Water 
  
Wash solution II 30 % v/v Ethanol 
 70 % v/v Water 
  
Sensitising solution 0.02 % v/v Sodium thiosulphate 
 99.98 % v/v Water 
  
Silver nitrate solution 0.2 % w/v Silver nitrate solution 
 0.026 % v/v Formaldehyde solution 




Developing solution 6 % w/v Sodium thiosulphate 
 0.0185 % v/v Formaldehyde solution 
  
Stop solution 50 % v/v Methanol 
 12 % v/v Acetic acid 
 38 % v/v Water 
  
Storage solution 5 % v/v acetic acid solution 
  
Wash Buffer (1x) 10 mM Tris-HCl, pH 7.5 
 0.1 % v/v Tween-20 
 100 mM NaCl 
    
 
3.4 EQUIPMENTS 
Following equipments were most frequently used during the course of this study. Others 
are cited in the Experimental Procedures. 
Appliance Manufacturer 
Centrifuge Biofuge 15R Herapus Sepatech, Osterode, Germany 
Centrifuge Sigma 3-18K Sigma, Osterode, Germany 
Consort Power Supply E815 Sigma, Steinheim, Germany 
Electrophoretic Transfer Cell BioRad, Munich, Germany 
Filtration pump SM18059 Sartorius, Göttingen, Germany 
Gel chambers BioRad, Munich, Germany 
Heater IKAMAG REO Schütt Labortechnik, Göttingen, Germany 
Laboratory balance Sartorius, Göttingen, Germany 
Lab-Shaker Braun, Melsungen, Germany 
Laminar Air Flow Safety Workbench  
BSB 4A Gelaire Flow Laboratories, Opera, Italy 
Mini Trans-Blot® Electrophoretic  
Transfer Cell BioRad, Munich, Germany 
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pH meter PB-11 Sartorius, Göttingen, Germany 
Speed vac SVC 10CH Savant, Holbrook, USA 
Thermo mixer comfort Eppendorf, Hamburg, Germany 
Vortexer REAX 2000 Heidolph, Schwabach, Germany 
Water bath GFL 1003 GFL, Burgwedel, Germany 
Water-jacketed CO2-Incubator Labotect, Göttingen, Germany 
 
3.5 SCIENTIFIC ONLINE SEQUENCES AND SOFTWARE SERVICES 
The following scientific software and databank sequences were used during the course of 
this study. 
      
Program Use Reference 
      
   
Blast Protein sequence database http://www.ncbi.nlm.nih.gov/blast/ 
   
Entrez Pubmed Sequence retrieval http://www.ncbi.nlm.nih.gov/entrez/ 
   
Mascot Protein database search www.matrixscience.com 
   
WinMDI Flow cytometric applications 
http://facs.scripps.edu/help/html/read1pt
l.htm 




4 EXPERIMENTAL PROCEDURES 
4.1 CELL CULTURE PROCEDURES 
HL-60 and A498 cell lines were maintained in RPMI and DMEM medium (Gibco, 
Paisley, UK) containing 5.5 mM D-glucose supplemented with 10 % fetal calf serum, 1 % 
L-glutamine and 1 % Penicillin/Streptomycin. Cells were routinely cultured and 
incubated until 70 % confluency in 75 cm² tissue culture flasks in a humidified 
5%CO2/95% air atmosphere at 37 °C. 
4.2 CELL VIABILITY ASSAY 
Cell viability was determined by standard trypan blue exclusion assay (Kaltenbach et al., 
1958). Briefly, control and MTX treated HL-60 cells were plated on 24-well dishes 
(Sarstedt, Newton, USA) at the density of 1×105 cells/mL in complete RPMI medium for 
72 hours at 37 °C. Subsequently, cells were harvested, washed with phosphate buffer 
saline (PBS) and 0.4 % trypan blue stain (Sigma-Aldrich, Missouri, USA) was added in 
equal volume of cell containing PBS buffer. Trypan blue positive and negative cells were 
counted using a haemocytometer (Hausser Scientific, Horsham, PA) under an ID 03 light 
Microscope (Zeiss, Oberkochen, Germany). 
4.3 DETECTION OF PHOSPHATIDYLSERINE BY ANNEXIN-V 
Apoptosis is associated by a loss of membrane phospholipids symmetry, resulting in the 
exposure of phosphatidylserine (PtdSer) at the plasma membrane (Fadok et al., 1992). 
This exposure of PtdSer was quantified by flow cytometry (Koopman et al., 1994), using 
the binding of fluorescein isothiocyanate (FITC) labeled annexin-V to PtdSer. Control 
and MTX treated HL-60 and A498 cells were incubated in complete RPMI and DMEM 
medium in a humidified 5 %CO2/95% air atmosphere at 37 °C for 72 hours. 
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Subsequently, cells were harvested, washed with PBS and centrifuged briefly for 200 x g 
at 4 °C. The annexin-V assay (Roche, Indianapolis, USA) was performed according to the 
manufacturer’s instructions. Briefly, cell pellet of each sample was resuspended in the 
provided binding buffer, centrifuged at 200 x g for 1 minute at 4 °C and again 
resuspended in 200 µL binding buffer. 5 µL of FITC labelled annexin-V conjugate was 
added into the sample and incubated for 15 min at 22 °C. The signal generated by 
FITC-labeled-annexin-V was analyzed in the FACSCalibur Flow Cytometer (BD 
Biosciences, Rockville, USA) using a single laser emitting excitation light at 488 nm. 
4.4 CELL LYSATE PREPARATION FOR TWO DIMENSIONAL GEL 
ELECTROPHORESIS 
Cell lysates were prepared as described by Dihazi and their colleagues (Dihazi et al., 
2005). Briefly, each group of HL-60 cells was centrifuged at 200 x g for 10 minutes at 
4 °C. The obtained cell pellet was further incubated in 0.3-0.5 mL lysis buffer containing 
9.5 M urea, 2 % w/v CHAPS, 2 % v/v ampholytes, 1 % w/v DTT, 10 mM PMSF at 4 °C 
for 30 minutes with intermittent vortexing. For removing cells debris, samples were 
centrifuged twice at 4500 x g for 45 minutes at 4 °C. The obtained lysates were either 
used immediately or were kept frozen at –80 °C until use. 
4.5 PROTEIN PRECIPITATION AND ESTIMATION 
Protein precipitation was done according to the instructions of Ready Prep 2D cleanup kit, 
provided by the manufacturer (Bio-Rad, Hercules, USA). Briefly, protein sample 
(100-500 µg) in a final volume of 100 µL was transferred into a 1.5 mL micro centrifuge 
tube. Then 300 µL of precipitating agent 1 was added and mixed by vortexing. After 
incubation on ice for 15 minutes, 300 µL of precipitating agent 2 was added and mixed by 
vortexing. The tubes were centrifuged at 4500 x g for 5 minutes to form a tight pellet. The 
EXPERIMENTAL PROCEDURES 
 22
supernatant was decanted and the tubes were repositioned as before and centrifuged at 
4500 x g for 5 minutes. Any residual liquid at the bottom of the tubes was removed. Then, 
40 µL of wash agent 1 was added on top of the pellet and the tubes were further 
centrifuged at 4500 x g for 5 minutes. The supernatant was removed and discarded. Ultra 
pure water (25 µL) was added to the tubes and mixed by vortexing 10-20 seconds. An 
additional 1 mL of wash agent 2 (pre-chilled at –20 °C for > 1 hour) and 5 µL of washing 
additive 2 were mixed by vortexing for 1 minute. During the following incubation period 
(at –20 °C for 30 minutes), the tubes were vortexed for 30 seconds at every 10 minutes 
interval. The pellet was formed by centrifugation at 4500 x g for 5 minutes. The 
supernatant was discarded and the pellet air-dried for < 5 minutes. The pellet was 
resuspended by adding lysis buffer followed by vortexing for 1 minute, incubation at 
room temperature for 3-5 minutes and vortexing again for 1 minute. The tubes were 
centrifuged at 4500 x g for 15 minutes to clarify the protein sample. The supernatant was 
then ready for isoelectric focusing (IEF). The obtained pure supernatants were used 
immediately for experiments or stored at –80 °C until analysis. Total protein 
concentration was measured according to the Bradford method (Bradford, 1976) using 
bovine serum albumin (Sigma, Steinheim, Germany) as a standard. 
4.6 PROTEIN CYDYES SATURATION LABELLING 
The CyDyes for saturation labelling have maleimide reactive groups. These dyes were 
covalently bound to the cysteine residues of proteins via a thioether linkage. To achieve 
maximal labelling of the cysteine residues, we used a high fluorchrome to protein 
labelling ratio protocol. CyDyes stock solutions were prepared by dissolving the solid 
dyes separately in high standard anhydrous DMF, aliquoting into 10 µL working solutions 
and stored at –80 °C. 5 µg of the protein samples (lysates from untreated vs. MTX-treated 
cells) were equalized with lysis buffer (containing no ampholytes and DTT) and 
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separately adjusted to pH 7.5 with appropriate acid/base titrations. For the reduction of 
protein cysteines, cell lysates were incubated with 2 nmol Tris (2-carboxyethyl) 
phosphine hydrochloride (TCEP; Sigma, Steinheim, Germany) at 37 °C in the dark for 






Figure 4. Schematic diagram of labelling reaction of protein thiols with maleimide 
CyDyes 
4 nmol CyDyes (Amersham Biosciences, Freiburg, Germany) were added to the reduced 
sample, vortexed, centrifuged briefly and kept at 37 °C in the dark for next 30 minutes. 
The labelling reactions were stopped with sample buffer containing DTT and ampholyte 
3/10 solution (Bio-Rad, Hercules, CA, USA) and finally, the contents were mixed well 






Figure 5. Workflow for cysteine labelled differential in-gel electrophoresis analysis 
Cysteine labelled differential in-gel electrophoresis of untreated and MTX treated HL-60 
cells were performed using Cy3 (green colour) and Cy5 (red colour) dyes, respectively. 
The protocol outlined above allows comparison of protein expression profiles, protein 
quantification, and identification of proteins of interest. 
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4.7 TWO DIMENSIONAL GEL ELECTROPHORESIS 
Each sample was diluted to a final volume of 315 µL in rehydration buffer (8 M urea, 1 % 
w/v CHAPS, 0.2 % v/v ampholytes pH 3-10, DTT 15 mM and traces of bromphenol 
blue). This mixture was further used for rehydration of IPG strip. The ReadyStripTM IPG 
strips (pH 3-10, 17 cm) were allowed to rehydrate for 1 hour before adding mineral oil 
(Bio-Rad, Hercules, USA). The passive hydrations of the IPG strips were carried out 
overnight at room temperature in a focusing chamber. The tray was transferred to the 
cooling platform of a PROTEAN IEF cell and isoelectric focusing was performed at 20°C 
using the following multisteps protocol shown in Table 1: 
 
Table 1. Multisteps protocol for isoelectric focusing of IPG strips 
Method Linear 
Rehydration Passive 
Run Temperature 20 °C 
IPG Strip pH 3 ~ 10, 17 cm 
Step 1 500 V Ramp: Time: 01:00 hour 
Step 2 1,000 V Ramp: Time: 01:00 hour 
Step 3 8,000 V Ramp: V hour: 32,000 V 
Step 4 500 V Hold Time: 10:00 hours 




After the first dimension, individual strip was equilibrated in 6 M urea, 30 % v/v glycerol, 
2 % w/v SDS, 0.05 M Tris-HCl, pH 8.8, and 15 mM DTT for 20 minutes. An additional 
incubation in the same buffer supplemented with iodoacetamide 400 mg/mL was carried 
out for another 20 minutes. The second dimension was performed overnight at 120 V 
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using a homogeneous polyacrylamide gel (12 % T, 200 mm x 230 mm x 1.5 mm) and 
applying continuous Laemmli buffer system (Laemmli, 1970). 
4.8 PROTEIN VISUALIZATION AND IMAGE ANALYSIS 
CyDyes labelled protein gels were scanned using a Fuji film FLA-5100 series imager 
(Fuji Photo, Kanagawa, Japan). The excitation and emission wavelengths are shown in 
Table 2. Silver staining was performed using a method described by Morrissey 
(Morrissey, 1981). Colloidal Coomassie staining was performed according to Neuhoff 
and their colleagues (Neuhoff et al., 1988). 
 
Table 2. Excitation and emission wavelengths used for imaging of fluorochrome 
labelled gels 
Bandwidths of the filters are shown in red and green colour 
FLA 5100 Series Imager 
 
Excitation filter (nm) Emission filter (nm) 
 
 
Cy3    532    Long pass 575 
 
Cy5   635   Long pass 665 
 
 
Fluorescent images were acquired in 16-bit TIFF files format and analysed by Delta2D 
software (Version 3.4; Decodon, Greifswald, Germany). For Coomassie and silver 
staining, digital images were obtained using Fuji film FLA-5100 series imager (Fuji 
Photo, Kanagawa, Japan). An image analysis was performed by Delta2D software 
(Decodon, Greifswald, Germany) and statistical analysis of protein variations was carried 




4.9 IN-GEL DIGESTION AND MALDI-TOF MS ANALYSIS OF PROTEIN 
SPOTS 
To permit identification of differentially expressed proteins from the saturation labeled 
gels, Coomassie brilliant blue or silver stained gels were performed. Differentially 
expressed protein spots were manually excised from the gels and washed with distilled 
water for 15 minutes. The destaining procedure for Coomassie stained protein spots was 
carried out with 50 % v/v acetonitrile (ACN) and 100 mM ammonium bicarbonate for 
5 minutes. For silver stained protein spots, destaining procedure was performed as 
described by Gharahdaghi et al., 1999. After destaining, in-gel digestion was performed 
with trypsin and the resulting peptide mixture was extracted with various concentrations 
of ACN and trifluoroacetic acid (TFA). Extracted peptide mixture was further dissolved 
in TFA and co-crystallised with 2, 5-dihydroxy-benzoic acid (matrix) on a stainless steel 
target using 1 µL matrix and 1 µL sample. An Applied Biosystems Voyager-DE STR 
time-of-flight mass spectrometer, operating in delayed reflector mode with an accelerated 
voltage of 20 kV was used to generate peptide mass map. Indiviual peptide mass map was 
obtained by averaging 50 individual laser shots. Obtained peptide masses were externally 
calibrated with a peptide mix of des-Arg-bradykinin ([M+H]+ 904.46), angiotensin I 
[(M+H) + 1296.68, Glu1-fibrinopeptide B (M+H)+ 1570.67, ACTH (1-17) (M+H)+ 
2093.08, ACTH (18-39) (M+H)+ 2465.19] and produced to search against protein 
sequences database. 
4.10 PEPTIDE SEQUENCE ANALYSIS 
To confirm the data obtained from mass finger print analyses, all samples were subjected 
to peptide sequence analyses. After in-gel digestion, extracted peptide mixture was 
dissolved in 0.1 % formic acid (FA). One µL of sample was introduced using a CapLC 
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auto sampler (Waters) onto a µ-precolumnTM Cartridge C18 pepMap (300 µm x 5 mm; 
5 µm particle size) and separated through a C18 pepMap100 nano Series TM (75 µm x 
15 cm; 3 µm particle size) analytical column (LC Packing, Amsterdam, Netherlands). The 
mobile phase consisted of solution-A containing 5 % ACN in 0.1 % FA  and solution B 
(95 % ACN in 0.1 % FA). Total sample run time was 60 minutes per sample analysis. 
Initially, samples were injected into a precolumn and washed with 0.1 % formic acid 
(30 µL) for 5 minutes. The washing step was followed by an elution step with an 
exponential gradient starting with 10 % and ending with 95 % solution B. The flow rate 
was decreased by a flow splitter from 5 µL/min pump to 0.25 nL/min. The precolumn 
was re-equilibrated with 0.1 % FA (20 µL/min) for another 5 minutes. The nanospray 
needle was held at 2 kV and the source temperature was at 40 °C. After chromatographic 
separation, peptide sequencing was performed on a Q-TOF Ultima Global (Micromass, 
Manchester, UK) mass spectrometer equipped with a nanoflow ESI Z-spray source in 
positive ion mode. Multiple charged peptide parent ions were automatically marked, 
selected in the quadruple fragmented in the hexapole collision cell and their fragment 
patterns were analysed by time of flight. The data acquisition was performed using 
MassLynx (v 4.0) software on a Windows NT PC, while data were further processed on a 
Protein-Lynx-Global-Server (v 2.1), (Micromass, Manchester, UK). 
4.11 DATABASE SEARCH AND PROTEIN IDENTIFICATION 
The raw data files were deconvoluted and deisotoped using Max Ent™ lite algorithm. 
This file format was further produced to search against Swissprot database 50.5 (230150 
sequences, 84479584 residues) through the web based Mascot search engine (MASCOT 
2.1) using following parameters: trypsin as an enzyme, monoisotopic, 1 possible missed 
cleavage, a peptide mass tolerance of 100 ppm, fragment mass tolerance of 0.6 Da and 
carbamidomethyl and methionine oxidation were considered as variable modifications 
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(Oxford, UK, http://www.matrixscience.com.search_form_select.html) (Perkins et al., 
1999). Results were scored using Probability Based Mowse Score (Protein score 
is-10*Log (p), where p is the probability that the observed match is a random event. 
Individual ions scores > 26 indicate identity or extensive homology (p<0.05). Only 
proteins with a minimum of one peptide identified and a protein score are > 26 in the 
peptide summary report were included in the protein identification list. 
4.12 WESTERN BLOT ANALYSIS 
Validation of our proteomic data (for proteins of interest) was performed by Western blot 
analyses (Burnette, 1981). After SDS–PAGE, blotting was performed on nitrocellulose 
membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK) at 250 mA for 
24 hours in transfer buffer (25 mM Tris-HCl, pH 8.4, 192 mM glycine, 0.5 % w/v SDS, 
20 % v/v methanol). The membranes were blocked in 5 % w/v non-fat dry milk in PBS 
containing 0.1 % v/v Tween-20 for 2 hours at 37 oC. The incubations with the following 
primary antibodies mouse anti-PDIA3 polyclonal antibody (Stressgen, Victoria, Canada), 
rabbit anti-PDIA4 polyclonal antibody (Stressgen, Victoria, Canada), mouse anti-ACTB 
monoclonal antibody, rabbit anti-HSPA5 polyclonal antibody (Sigma-Aldrich, Missouri, 
USA), mouse anti-CALR monoclonal antibody (BD Bioscience, Rockville, USA), rabbit 
anti-NF-κB subunit p65 monoclonal antibody (Santa Cruz, CA, USA) and mouse anti-
TPI polyclonal antibody (Abnova, Taiwan, China) were carried out for 1 hour at 37 °C. 
After washing, membranes were incubated with 1:1200 dilution of horseradish 
peroxidase-conjugated sheep anti-mouse antibody or 1:12000 horseradish peroxidase-
conjugated donkey anti-rabbit antibody (Amersham Biosciences, Freiburg, Germany) for 
another 60 minutes at 37 °C. To visualize the protein bands, nitrocellulose membranes 
were washed with PBS containing 0.1 % v/v Tween-20 and treated with Western blotting 
luminal reagent (Perkin Elmer, Boston, USA). Finally, results were obtained on a Kodak 
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film and quantified by densitometry using the Multi Analyst Software (Bio-Rad 
Laboratories, CA, USA). 
4.13 PYRUVATE KINASE ACTIVITY ASSAY 
Pyruvate kinase activity assay was assessed by continuous spectrometric rate 
determination method as described by Ainsworth et al. (Ainsworth and MacFarlane, 
1973). HL-60 and A498 cells were grown in 75 cm² culture flasks at the cell density of 
5x107 cells/mL in the corresponding medium. Cells were trypsinized and centrifuged at 
200 x g for 10 minutes at 4 °C. Obtained cell pellets were disrupted by vortexing in assay 
buffer (100 mM potassium phosphate buffer, pH 7.6 at 37 oC) with addition of an equal 
volume of glass beads. For removing cell debris, cell lysates were centrifuged twice at 
4500 x g for 10 minutes at 4 oC. Supernatants were used directly for enzymatic assay. An 
aliquot of supernatant from the disrupted cells was added to a solution containing 39 mM 
potassium phosphate, 0.58 mM phospho (enol) pyruvate, 0.11 mM NADH, 6.8 mM 
magnesium sulphate, 1.5 mM ADP, and 10 units of lactate dehydrogenase. Activity was 
determined through Lambda 25 UV/VIS Spectrophotometer (Perkin Elmer Life Sciences, 
Rodgau-Jügesheim, Germany) at the rate of absorbance decrease 340 nm with 1 unit 
corresponding to the oxidation of 1 pmol of NADH per minute at 37 oC. 
4.14 ANALYSIS OF MITOCHONDRIA MEMBRANES POTENTIAL 
Mitochondrial membrane potential (∆ψm) is measured in intact cell by loading the cytosol 
or the mitochondrial matrix with calcein, a hydrophilic 620 Da fluorochrome that 
normally does not cross the inner membrane (Kroemer et al., 1998; Bernardi et al., 1999). 
Alternatively, ∆ψm can be assessed indirectly using a fluorochrome 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethyl-benzimidazolcarbocyanine iodide (JC-1). JC-1 (Invitrogen, Karlsruhe, 
Germany), a cationic dye that indicates mitochondrial polarization by shifting its 
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fluorescence emission from green (~525 nm) to red (~590 nm) (Smiley et al., 1991). 
Untreated and MTX treated cells were resuspended in 1 mL culture medium, stained with 
a final concentration of 10 µg/mL JC-1 and incubated for 10 min at 37 °C. The 
elimination of unbound dye was carried out by washing the cells twice with culture media 
and immediately quantified by FACSCalibur Flow Cytometer (BD Biosciences, 
Rockville, USA). Cells in which the ∆ψm was maintained accumulate so-called J-
aggregates indicated by the red fluorescence, whereas those with a collapsed ∆ψm shown 
green fluorescence. Data analyses were performed by Cell Quest software that works 
under Windows 3.1 or Windows 95, i.e. WinMDI (written by Dr. Joe Trotter, Scripps 
Research Institute, La Jolla, CA, USA). 
4.15 DETECTION OF ROS 
Reactive oxygen species (ROS) formation was quantified by staining with 
dihydrorhodamine 123 (DH-123, Sigma-Aldrich Chemie GmbH, Steinheim, Germany), a 
cell-permeable non-fluorescent compound that is oxidized by cellular peroxides to 
fluorescent rhodamine (Dugan et al., 1995). Untreated and MTX treated A498 cells were 
resuspended in 5 mL culture medium, stained with 500 µM DH-123 and incubated for 
2 hours at 37 °C. After washing cells with culture medium, fluorescence images (Zeiss 
Axiovert 100 TV) were obtained using appropriate excitation and emission wavelengths. 
Images were captured immediately after illumination (25 msec exposure). 
Photomicrograph of random 40 x field was analysed using Analysis Doku(R) software 
(Soft imagine systems, Muenster, Germany). 
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4.16 STATISTICAL DATA ANALYSIS 
MTX dose dependent response curves were obtained by non-linear regression analysis 
using the software Sigma Plot 8.0 (SYSTAT software, Chicago, Illinois). The data were 
fitted to the sigmoid Emax model as described by (Bourgeois, 1988). 
 
Edrug is the measured effect of the drug at a certain dose. Edrug starts at Emax and goes to 
Emin with a sigmoid shape. Note that TD60 in our experiment indicates the dose that gives 
sixty-percentile maximal effect. Results are shown as means ± S.D. of three independent 






APL cells serve as a paradigmatic cell model in biological and clinical leukaemic 
research. Several cell lines have been derived from APL patients. Some of these cell lines 
such as HL-60, NB-4 and PL-21 are most commonly used in leukaemic research. 
Especially, the HL-60 cell line has attracted the most leukaemic research interest. Its 
capacity to differentiate in vitro to a variety of different cell types of the myelomonocytic 
lineage is the characteristic feature of HL-60 cells. Therefore, studies with HL-60 cells 
have been proved to be invaluable in various areas, which include the following: 
1. Providing insights into the control of mechanisms of normal granulocytes 
/monocytes/macrophage differentiation. 
2. Suggesting an unique in-vitro model for studying the cellular and molecular 
events involved in the proliferation and differentiation of APL against various 
chemotherapeutic agents. 
3. Serving as an valuable model for studying the specific cellular oncogene 
expression in relationship to particular haematopoietic differentiative lineage 
(Collins, 1987; Birnie, 1988). 
5.1 MTX DEMONSTRATES CELL TOXICITY ON HL-60 CELLS 
To elucidate the effect of MTX on HL-60 cells, we treated these cells with increasing 
concentrations of MTX (0 to 11 µM) for 0, 24, 48, and 72 hours. Trypan blue exclusion 
assay showed a progressive decrease in cell viability with increasing concentrations of 
MTX for the indicated time periods (Figure 6). Minimum cell viability was obtained after 
exposing HL-60 cells to 11 µM MTX for 72 hours. The MTX concentration that led to a 
60 % mean reduction of cell viability (IC60) was calculated and found to be 2.5 µM. This 





Figure 6. Impact of MTX on HL-60 cells 
HL-60 cells were treated with wide range of MTX concentrations (0.0 to 11 µM) for 24, 
48 and 72 hours. Cell viability was determined by standard trypan blue exclusion assay at 
above-mentioned time periods and presented as percentage in Y-axis. Results are given as 
the mean values ± S.D. of % cell viability from three independent experiments. 
* p < 0.05, ** p < 0.001. 
5.2 MTX INDUCES APOPTOSIS IN HL-60 AND A498 CELLS 
To address the question, whether the initial cell death observed in MTX treated HL-60 
cells was due to apoptosis or necrosis, we investigated the morphological features of 
HL-60 cells during the exposure to MTX using normal light microscopy and flow 
cytometry. Several investigators have previously shown that cells undergoing apoptosis 
have decrease in forward light scatter and increase in side light scatter depicting loss of 
cell volume and increase in cell granularity, respectively (Dive and Hickman, 1991; 
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Nicoletti et al., 1991; Zamai et al., 1993). Our microscopic and flow cytometric analysis 
in HL-60 cells revealed the same cell shrinkage and induction of cellular granularity after 
addition of 2.5 µM MTX for 72 hours (Figure 7A&B). 
 
 
Figure 7. Morphological changes observed in HL-60 cells after MTX treatment 
HL-60 cells were incubated without or with 2.5 µM MTX in RPMI medium for 72 hours 
and morphological changes were observed using: (A) Normal light microscopy. 
Apoptotic cells are shown in upper right panel and depict by black and white arrows. The 
photograph was documented at an exposure of 20x magnification. (B) Flow cytometry. 
Results are plotted as forward scatter (FSC) against side scatter (SSC). Increased cellular 
granularity (%) is shown inside the marked oval circle (lower panels). 
We further confirmed our preliminary apoptotic observations by PtdSer exposure. 
Exposure of PtdSer in untreated and MTX treated HL-60 cells were measured using 
FITC-labelled-annexin-V staining assay as described in the Experimental Procedures. An 
increase in the percentage of apoptotic cells having PtdSer exposure was detected in MTX 





cells showed an increase in translocation of PtdSer at the plasma membrane as compared 
to untreated cells (Figure 8A). To establish whether other cancer cells show MTX 
induced PtdSer exposure, we investigated the effect of MTX on A498 cells. MTX 
resulted in differential degree of PtdSer exposure in A498 cells (Figure 8A). Moreover, 
both PtdSer translocation and cell membrane permeability (trypan blue positive cells) 
occurred simultaneously in MTX treated HL-60 cells. This was illustrated by plotting the 
percentages of cells having undergone PtdSer translocation and cell permeability in 






Figure 8. Assessment of apoptosis by FITC-labelled-annexin-V staining assay 
HL-60 and A498 cells were incubated with or without 2.5 µM and 45 µM MTX 
respectively for 72 hours, stained with FITC-labelled-annexin-V and analysed by flow 
cytometry. (A) MTX induces PtdSer exposure. Numbers above the histogram markers 
indicate the percentage of apoptotic cells in a representative experiment. Similar results 
were obtained in two additional experiments with different passages of cells. 
(B) Percentage of MTX affected HL-60 cells having translocated PtdSer (annexin V 
positive cells) and died (trypan blue positive) cells shown in Y-axis as a function of the 





To determine the sequence of apoptotic events, we replotted MTX treated HL-60 cell data 
(∆ψm, cell morphology and PtdSer exposure) in the same graph. In HL-60 cells, cell 
shrinkage, PtdSer exposure and induction of cellular granularity induced by MTX were 
preceded by the loss of ∆ψm. HL-60 cells exhibited a reduction in the ∆ψm at 24 hours 
after MTX treatment, whereas at this time point no loss of cell shrinkage has occurred and 
neither translocation of PtdSer nor induction of cellular granularity were detected; yet 
∆ψm was already perturbed (Figure 9). 
 
 
Figure 9. Morphological events of apoptosis examined by flow cytometry 
HL-60 cells were incubated without or with 2.5 µM MTX in RPMI medium for 24, 48 
and 72 hours. ∆ψm disruption (MMP), cell shrinkage (FSC), cell granularity (SSC) and 
translocation of PtdSer at the cell surface (FITC-labelled-annexin-V) were evaluated by 
flow cytometry (described in the Experimental Procedures) as a function of the indicated 
time periods (X-axis). These morphological events of apoptosis were observed by 
replotting the obtained data in the same graph. 
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5.3 EVALUATING EXPERIMENTAL REPRODUCIBILITY OF THE 
CYSTEINE LABELLED IN-GEL ELECTROPHORESIS APPROACH 
To characterize the molecular targets of MTX induced apoptosis in the analysed cancer 
cell lines, we performed cysteine labelled differential in-gel electrophoresis approach. In 
this approach, a new set of cysteine labelled CyDyes has been used for labelling protein 
samples. Wide dynamic wavelength, high sensitivity and reproducibility (Shaw et al., 
2003) appeared to make these dyes suitable to identify intracellular protein changes 
involved in MTX induced apoptosis. Moreover, these dyes enable to visualize large scale 
protein expression profile from small amounts of protein samples such as those obtain 
from laser-micro dissected tissues (Kondo et al., 2003) and primary cultured hepatocytes 
(Fujii et al., 2005). In addition to this, cysteine labelling CyDyes have been successfully 
implicated in the proteomic study of adenoma of Min mice (Kondo et al., 2003), 
hepatocellular carcinoma tissue (Fujii et al., 2005), haematopoietic cells (Evans et al., 
2004), and identifying free thiols from native protein extract of seeds (Maeda et al., 
2004). 
To control the CyDyes labelling artifacts, we compared CyDyes labelled protein spots 
profile with traditional silver stain. Although, the overall protein spots pattern between the 
silver staining and CyDyes labelled was quite similar, yet subtle differences were 
detected. These differences in the protein spots were probably dependent on the high/low 
abundance of cysteine residues in the proteins. For example, some proteins such as 
fructose-bisphosphate aldolase A (ALDOA) and ATP synthase subunit α (ATP5A1) on 
the silver stain gels consistently showed reduce labelling intensity on the Cy5 labelled gel 
image section in MTX treated HL-60 cells (Figure 10). This has been a criticism of 
cysteine-modifying fluorophores (Berggren et al., 2001), when used for global proteomic 
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studies. In spite of this drawback, the cysteine labelling CyDyes still offer promising 
advantages over other conventional protein detection techniques. 
 
 
Figure 10. Partial view of two-dimensional gel electrophoresis; gels obtained from 
MTX treated HL-60 cell lysates visualised by silver stain or Cy5 dye 
2.5 µM MTX treated samples were prepared, resolved on two-dimensional gel 
electrophoresis and visualised by silver staining or Cy5 labelled as described in the 
Experimental Procedures. The type of protein detection technique is indicated in the top 
right corner of each gel image section. Marked arrows and circles depict visible protein 
spots in silver stained HL-60 cells as compared to Cy5 labelled gel image section. 
Labelling of the spots correspond to the genes name as assigned in Table 4. 
In order to evaluate the experimental reproducibility of cysteine labelled two-dimensional 
gel spot profiles, four independent untreated samples of HL-60 cell lysates were labelled 
with Cy3 dye. Cysteine labelled differential in-gel electrophoresis was performed as 
described in the Experimental Procedures. After analysing the gels with Delta 
2D software, approximately 500 spots from a well-resolved area of the gels were selected 
(those spots could be matched on all control gels) and quantified the protein 
spot % volume data by Delta 2D software. The resulted data were plotted on a log scale in 
both axis and correlation coefficients were calculated for the data sets using Sigma Stat 
version 8. We observed a good experimental reproducibility by comparing of the different 
gel images with correlation coefficients between 0.74 - 0.92 (Figure 11) confirming that 
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Figure 11. Evaluation of experimental reproducibility by Scatter Plot analysis 
Scatter plots analysis of four independent untreated (control) samples of HL-60 cell 
lysates were labelled with Cy3 dye and resolved on two-dimensional gels as described in 
the Experimental Procedures. Cy3 labelled control gels were analysed with Delta 2D 
software. Approximately 500 protein spots from a well-resolved area of the gels were 
selected, quantified and plotted on a log scale in both axis. Correlation coefficient (Rsqr) 
was further calculated for each paired protein data set of two control sample lysates and 
shown in above-mentioned figure. 
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5.4 IDENTIFICATION OF DIFFERENTIALLY EXPRESSED PROTEINS 
IN MTX TREATED HL-60 CELLS 
After establishing the protocol in a reproducible manner, we prepared three independent 
sets of protein cell lysates from untreated and 2.5 µM MTX treated HL-60 cells obtained 
after 72 hours. Each set of cell lysate was labelled with Cy3 and Cy5 dyes, respectively. 
The corresponding Cy3 and Cy5 labelled samples were mixed and co-resolved on the 
two-dimensional gel electrophoresis (as described in the Experimental Procedures), to 
achieve high accuracy for the protein quantification. Figure 12 represents an example of 
large dual colour two-dimensional image of HL-60 cell proteome obtained from untreated 
and MTX treated HL-60 cell lysates labelled with CyDyes. Cy3 labelled proteins are 
shown in green colour (represent untreated HL-60 cell proteome) and Cy5 labelled 
proteins are in red colour (represent 2.5 µM MTX treated HL-60 cell proteome). 845 and 
878 protein spots were detected by Delta 2D software in untreated and 2.5 µM MTX 
treated samples, respectively. Significant differences in the proteins expression were 
found in the untreated and MTX treated samples as shown in Table 3. Although, we 
found more than 800 paired overall protein spots in the different sample sets, 492 protein 
spots were present in all the three sets of untreated and MTX treated gels. Therefore, we 
included 492 protein spots in the differential proteome analysis of untreated and MTX 
treated HL-60 cells to achieve statistical confidence. Altogether, 230 protein spots were 
almost equally abundant in both cell proteomes leading to the yellow colour overlay. 
81 protein spots were differentially expressed (p < 0.05) in the MTX treated HL-60 cell 
proteome. We considered significant all the quantitative differences with a variation of at 
least three times in % spot volume data with the Student's t-test statistical probability less 
than 0.05 (p < 0.05). Using Q-TOF Ultima Global (Micromass, Manchester, UK) 
equipped with a nanoflow ESI Z-spray and an Applied Biosystems Voyager-DE STR 
RESULTS 
 43
time-of-flight mass spectrometer, we identified 24 differentially expressed proteins from 
MTX treated HL-60 cell proteome having different biological functions. Table 4 shows 
the list of the proteins identified by database search, which are arranged according to their 
respective role in metabolic or signalling pathways. It could be precluded that the 
detection limits of the applied mass spectrometry would limit the identification of 







Figure 12. Large dual colour two-dimensional image of proteins expression profile 
obtained from untreated and MTX treated HL-60 cell lysates labelled with 
corresponding CyDyes 
HL-60 cells were incubated without or with 2.5 µM MTX in RPMI medium for 72 hours. 
Cysteine labelled differential in-gel electrophoresis was performed using CyDyes as 
described in the Experimental Procedures. Differentially expressed protein spots were 
excised out. After in-gel digestion with trypsin, extracted peptide mixture was analysed 
by mass spectrometry and identified by database search. Cy3 labelled proteins are shown 
in green colour (represent untreated HL-60 cell proteome) and Cy5 labelled proteins are 
in red colour (represent 2.5 µM MTX treated HL-60 cell proteome). Arrow marked spots 
are the differentially expressed proteins obtained after 72 hours MTX treatment. 
Labelling of the spots correspond to the genes name as assigned in Table 4. 
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Table 3. Summary of untreated and MTX treated HL-60 proteome analysed by Delta 2D software 
  
Number of protein spots detected in the control HL-60 proteome 845 
  
Number of protein spots detected in the MTX treated HL-60 proteome 878 
  
Number of protein spots matched in all gels 492 
  
Number of high abundant protein spots in MTX treated HL-60 proteome (fold change more than 5.0) 36 
  
Number of up regulated protein spots in MTX treated HL-60 proteome (fold change 1.5-5.0) 89 
  
Number of low abundant protein spots in MTX treated HL-60 proteome (fold change less than 0.5) 45 
  





Table 4. List of the proteins that were differentially expressed in HL-60 cells during treatment with 2.5 µM MTX for 72 hours 
Abbreviation Swiss Prot (Acc. No.) Name of protein Molecular weight (Da) pI value No. of peptide matched** MS Score*§ 
              
 
Endoplasmic Reticulum Chaperones 
$CALR P27797 Calreticulin precursor 48112 4.3 3 89 
HSPA5 P11021 78 kDa Glucose regulated protein precursor 72288 5.0 23 989 
Proteasome Complex subunits 
PSMA4 P25789 Proteasome subunit alpha type 4 29465 7.2 9 236 
PSMA5 P28066 Proteasome subunit alpha type 5 26394 4.8 8 274 
PSMA7 o14818 Proteasome subunit alpha type 7 27870 7.8 6 255 
PSMB3 P49720 Proteasome subunit beta type 3 22933 5.9 7 215 
PSMC5 P62195 26S Protease regulatory subunit 8 (p45/SUG) 45597 7.1 9 300 
PSMC6 P62333 26S Protease regulatory subunit S10B 44145 7.0 10 362 
       
Mitochondrial Transmembrane Electron Transport System 
ACO2 Q99798 Aconitate hydratase 85372 7.3 8 177 
ATP5B P06576 ATP synthase subunit beta 56525 5.3 19 677 
ATP5A1 P25705 ATP synthase subunit alpha 59714 7.7 7 141 
HSPA9B P38646 Stress-70 protein, mitochondria precursor 73635 6.0 19 831 
SOD2 P04179 Superoxide dismutase (Mn) 24707 6.9 1 34 
UQCRC1 P31930 Ubiquinol-cytochrome-c reductase complex core protein I 52612 5.6 6 135 
HADHSC Q16836 Short chain 3-hydroxy-CoA dehydrogenase 34256 8.3 4 121 
PDHB P11177 Pyruvate dehydrogenase E1 component subunit beta 39194 5.5 11 392 
 
 
      
Glycolytic Cycle 
$ALDOA P04075 Fructose-bisphosphate aldolase A 39264 8.3 8 242 
GAPDH P04406 Glyceraldehyde-3-phosphate dehydrogenase 35899 8.5 24 536 
LDH-A P00338 L-lactate dehydrogenase A chain 36534 7.9 8 349 
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PKM2 P14618 Pyruvate kinase, isoenzymes M1/M2 57769 7.9 15 690 
       
Signal Transduction Related Proteins 
ARHGDIB P52566 Rho-GDP-dissociation inhibitor 2 22843 5.1 4 121 
RANBP1 P43487 Ran-specific GTPase-activating protein 23296 5.1 7 283 
CALM2 P62158 Calmodulin 16696 4.1 7 187 
Others 
AHSG P02765 Alpha-2-HS-glycoprotein precursor 39300 5.2 4 149 
FUBP1 Q96AE4 Far upstream element-binding protein 1 67431 7.1 9 268 
       
* Ions score is -10*Log (P), where P is the probability that the observed match is a random event. Individual ions scores >27 indicate identity or extensive homology (P < 0.05).  
§ All proteins identified by Q-TOF MS      
** Detailed peptides information are provided in Appendix 
$ Not visualised in Cydyes labelled gel images     
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5.4.1 MTX down regulates proteasome subunits in HL-60 cells 
The proteasome, an ATP-dependent protease, modulates intracellular protein degradation 
(Voges et al., 1999). The multi-enzyme protease consists of a 20S core catalytic complex 
and two 19S regulatory subunits. The 20S core is a hollow, barrel shaped protein complex 
(Kisselev and Goldberg, 2001) composed of four stacked rings with an overall 
architecture of α (1-7) β (1-7) β(1-7) α(1-7). The two outer α rings form-gated channel 
through which substrates enter and products exit the catalytic core. In addition, α subunits 
are also required for the recognition of ubiquitin tagged substrates and the unfolding of 
substrates prior to their threading into the proteolytic chamber (Glickman and 
Ciechanover, 2002). Interestingly, cysteine labelled differential in-gel electrophoresis 
analysis revealed that MTX significantly decreased the protein expression (% spot 
volume data) of two structural proteasome subunits type α4, and α7 (PSMA4 and 
PSMA7), a non-catalytically proteasome subunit type β3 (PSMB3) and two 26S protease 
regulatory subunits 8 (p45/SUG) and S10B (PSMC5 and PSMC6) from MTX treated 
HL-60 cells (Figure 13A&B). One structural proteasome subunit type α5 (PSMA5) 
showed a statistical tendency of down regulation (% spot volume data) in MTX treated 
HL-60 cells. In contrast, the % spot volume data of 78 kDa glucose regulated protein 
precursor (HSPA5) was found to be 0.46 ± 0.02 (p < 0.05) in MTX treated HL-60 cells as 
compared to untreated where the % spot volume data was 0.375 ± 0.005 (Figure 12). 
Similarly, the % spot volume data of calmodulin-2 (CALM2), a calcium binding protein 
was found to be 0.29 ± 0.06 (p < 0.09) in MTX treated HL-60 cells as compared to 













Figure 13. Down regulation of six proteasome subunits in MTX treated HL-60 cells 
HL-60 cells were incubated without or with 2.5 µM MTX in RPMI medium for 72 hours. 
Samples were then subjected to cysteine labelled differential in-gel electrophoresis using 
corresponding CyDyes for each sample. (A) Boxed areas in representative dual colour 
two-dimensional fluorescent image (A-B) have been enlarged and the corresponding 
close up mark areas (arrow and circle) of the gel image showing decrease expression of 
proteasome subunits (PSMA4, PSMA5 and PSMA7) in MTX treated HL-60 cell 
proteome. (B) Boxed areas in representative dual colour two-dimensional fluorescent 
image (C-D) have been enlarged and the corresponding close up mark areas (arrow and 
circle) of the gel image showing decrease expression of proteasome subunits (PSMB3, 
PSMC5 and PSMC6) in MTX treated HL-60 cell proteome. The protein expression 
quantification is presented as % volume of spot (Y-axis) in front of enlarged boxed areas. 
Labelling of the spots correspond to the gene names as assigned in Table 4. Cy3 labelled 
proteins are shown in green colour (represent untreated HL-60 cell proteome) and 
Cy5 labelled proteins are in red colour (represent 2.5 µM MTX treated HL-60 cell 
proteome). Results are given as the mean values ± S.D. of % volume of spot from three 





5.4.2 Differential effect of MTX on glycolytic and MTETS pathways 
Another important finding of this study revealed the impact of MTX on the carbohydrate 
metabolism in both type of cancer cells analysed by combined approaches. Cysteine 
labelled differential in-gel electrophoresis combined with mass spectrometry analyses 
showed that the protein expression (% spot volume data) of several glycolytic enzymes 
such as glyceraldehydes-3-phosphate dehydrogenase (GAPDH), pyruvate kinase 
isoenzymes M1/M2 (PKM2) and L-lactate dehydrogenase A chain (LDH-A) were 
significantly increased in MTX treated HL-60 cells (Table 5). The inductions of the 
pyruvate kinase (PKM2) activity (p < 0.05) and triosephosphate isomerase (TPI) were 
confirmed with enzyme activity assay and Western blotting, respectively 
(Figure 14A&B).  This reflected to a stimulation of the glycolytic pathway by MTX in 
both cancer cell lines. In contrast, the expression (% spot volume data) level of pyruvate 
dehydrogenase E1 component subunit beta (PDHB) showed a statistical tendency of 
down regulation in MTX treated HL-60 cells (Table 5). 
Table 5. Over expression of glycolytic enzymes in MTX treated HL-60 cells 
Name of the protein Control MTX treated Detection Method Figure Reference 
ALDOA -- Up regulated SS         Not shown 
TPI §1.00 ± 00.00 1.69 ± 0.07 WB Figure 15B 
GAPDH $10.14 ± 0.005 13.91 ± 0.33* CL-DIGE Figure 12 
PKM2 ∆0.99 ± 0.09 8.00 ± 0.18* CL-DIGE & EAA Figure 12&15A 
LDH $0.08 ± 0.01 0.22 ± 0.03* CL-DIGE Figure 12 
PHDB $0.36 ± 0.018 0.27 ± 0.01 CL-DIGE Figure 12 
§ The protein expression quantification of spots is presented as % volume of spot in CL-DIGE. 
$ Protein expression profile of TPI was quantified by densitometry and presented as densitometric units of 
the probe/densitometric units of the ACTB. 
∆ PKM2 activity was assessed by spectrophotometer and result is presented as units/mg of protein 
   All results are given as the mean values ± S.D. of three independent experiments, * p < 0.05. 
   Abbreviations: SS, silver staining; WB, Western blotting; CL-DIGE, Cysteine labelled differential in-gel 




Figure 14. MTX induces pyruvate kinase activity and increases the expression of 
triosephosphate isomerase (TPI) in HL-60 and A498 cancer cells 
HL-60 and A498 cells were incubated without or with 2.5 µM and 45µM MTX 
respectively in corresponding mediums for 72 hours. Pyruvate kinase activity assay and 
western blotting were performed as described in the Experimental Procedures. (A) Effect 
of MTX on pyruvate kinase activity shown in above mentioned cancer cell lines. Pyruvate 
kinase activity was measured by spectrophotometer at the wavelength of 340 nm and 
presented as units/mg of protein in Y-axis. Results are given as the mean values ± S.D. of 
three independent experiments, * p < 0.05. (B) Representative blots and bar diagrams 
depict the induction of TPI expression in MTX treated HL-60 and A498 cell lines in a 
time dependent manner whereas β-actin (ACTB) was used as an internal standard. Protein 
expression profile was quantified by densitometry and presented as densitometric units of 
the probe/densitometric units of the ACTB. The protein expression quantification was 
presented as grouped bar chart with error bars. Each bar represents the mean ratios ± S.D. 
of protein intensity on the blots from three independent experiments. 
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Similarly, seven mitochondrial-localized proteins were differentially expressed in MTX 
treated HL-60 cells that attributed to MTETS and beta-oxidation pathways. The protein 
expression (% spot volume data) level of one mitochondrial precursor ATP synthase 
subunit beta (ATP5B; oxidative phosphorylation), (Figure 17A) two enzymes such as 
aconitate hydratase (ACO2; tricaboxylic acid cycle) and short chain 3-hydroxy-CoA 
dehydrogenase (HADHSC; beta-oxidation pathway) were significantly decreased in MTX 
treated HL-60 cells as compared to untreated. Similarly, the protein expression (% spot 
volume data) of superoxide dismutase Mn (SOD2) belonging to the intra-mitochondrial 
free radical scavenging enzyme was markedly down regulated (p < 0.05) in MTX treated 
HL-60 cells (Figure 15). In contrast, the expression (% spot volume data) of three-
mitochondrial proteins such as mitochondrial precursor ATP synthase subunit alpha 
(ATP5A1) (Figure 17A), Ubiquinol cytocrome-c reductase complex core protein I 
(UQCRC1), and one stress-70 mitochondrial precursor (HSPA9B) were significantly 
increased in HL-60 cells after exposure to MTX for 72 hours (Figure 15). To elucidate 
whether MTX induced apoptotic protein profiles were cell specific, we performed the 
conventional proteomic analysis in A498 cells with and without MTX treatment for 72 
hours. We found the similar results with majority of the proteins, yet subtle differences 
were detected. Moreover, the differences in protein expression profiles were found to be 






Figure 15. Differential expression of mitochondrial proteins in MTX treated HL-60 
cell line 
HL-60 cells were incubated without or with 2.5 µM MTX in RPMI medium for 72 hours. 
Samples were subjected to cysteine labelled differential in-gel electrophoresis using 
specific CyDyes for each sample. Differentially expressed protein spots were quantified 
with Delta 2D software and plotted it on a bar diagram. The protein expression 
quantification data is presented as % volume of spot (X-axis) and labelling of the spots 
corresponds to the gene names as assigned in Table 4. Results are given as the mean 
values ± S.D. of % volume of spot from three independent experiments, * p < 0.05. 
5.5 MTX INDUCES ER STRESS IS LINKED TO ALTERATION IN THE 
PROTEASOME PROTEIN EXPRESSION 
The proteasome is responsible for degradation of many intracellular proteins, thereby 
helping to maintain the cellular homeostasis during biological processes such as cell 
cycle, signal transduction, response to stress and gene transcription (Hershko and 
Ciechanover, 1998). Among other functions, the proteasomal complex rapidly degrades 
misfolded proteins to avoid accumulation of dysfunctional proteins (Kaufman, 2002; Ron, 
2002). Moreover, proteasome inhibitors are known to act through the NF-κB pathway. 
RESULTS 
 55
This pathway is constitutively active in many types of cancer cells and is associated with 
cell proliferation, survival and protection from chemotherapy induced apoptosis (Wang et 
al., 1999). According to our Western blot and proteomic findings, MTX treated cancer 
cells showed decrease expression of the NF-κB subunit p65 (Figure 16B), which might 
be associated with an inhibition of proteasome subunits. This could lead to an increased 
accumulation of misfolded proteins in ER resulting in an ER stress response. To confirm 
the biological significance of our protein data, Western blot analyses were further 
performed to directly examine changes of the protein expression of ER chaperones. 
Interestingly, ER chaperones such as calreticulin precursor (CALR), protein disulphide 
isomerase A3 precursor (PDIA3), protein disulphide isomerase A4 precursor (PDIA4) 
and 78 kDa glucose regulated protein precursor (HSPA5) were continuously up regulated 






Figure 16. Western blot analyses of ER chaperones and NF-κB affected by MTX in 
HL-60 and A498 cancer cells 
Representative bar diagrams and blots depict the changes of protein expression profile in 
MTX treated HL-60 and A498 cells, whereas β-actin (ACTB) was used as an internal 
standard. (A) Calreticulin precursor (CALR), protein disulphide isomerase A3 precursor 
(PDIA3), protein disulphide isomerase A4 precursor (PDIA4) and 78 kDa glucose 
regulated protein precursor (HSPA5) (B) NF-κB. Protein expression profile was 
quantified by densitometry and presented as densitometric units of the 
probe/densitometric units of the ACTB. The expression quantification is presented as 
grouped bar chart with error bars. Each bar represents the mean ratios ± S.D. of protein 
intensity on the blots from three independent experiments. 
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5.6 MTX ALTERS MITOCHONDRIAL MEMBRANE POTENTIAL AND 
GENERATES ROS 
The ATP synthase subunits catalyse ATP synthesis, utilizing an electrochemical gradient 
of protons across the inner membrane during oxidative phosphorylation and thus provide 
its function in energy transduction. In addition to these well established functions, 
multisubunits complex ATP synthase was recently shown to have a role in determining 
the ultrastructure of mitochondria (Arselin et al., 2003; Giraud et al., 2002; Paumard et 
al., 2002; Soubannier et al., 2002). Cysteine labelled differential in-gel electrophoresis 
analysis revealed that two proteins such as ATP synthase subunits alpha and beta 
(ATP5A1 and ATP5B) were differentially expressed in term of the % spot volume data in 
MTX treated HL-60 cells (Figure 17A). Furthermore, to determine the impact of ATP 
synthase subunits on MTX mediated apoptosis, the cationic cell-permeable JC-1 dye was 
utilized to calculate the electric potential of the membrane in both cell lines. We found 
that ∆ψm was continuously dissipated in MTX treated HL-60 and A498 cells during the 
indicated time periods (Figure 17B). The differential proteins expression of ATP 
synthase subunits by MTX might causes structural alterations in the ∆ψm. These 
alterations in the ATP synthase subunits may play an important role in the collapse of 





Figure 17. MTX induces apoptosis is associated with altered mitochondrial 
membrane potential 
(A) HL-60 cells were incubated without or with 2.5 µM MTX in RPMI medium for 72 
hours. Cysteine labelled differential in-gel electrophoresis was performed using specific 
CyDyes for each sample. Boxed areas in representative dual colour two-dimensional 
fluorescent image (A&B) have been enlarged and the corresponding close up mark areas 
(arrow and circle) of the gel showing differential expression of ATP synthase subunits 
alpha & beta (ATP5A1 and ATP5B) in MTX treated HL-60 cell proteome. The protein 
expression quantification was presented as % volume of spot (Y-axis) in front of enlarged 
boxed areas. Labelling of the spots correspond to the gene names as assigned in Table 4. 
Cy3 labelled proteins are shown in green colour (represent untreated HL-60 cell 
proteome) and Cy5 labelled proteins are in red colour (represent 2.5 µM MTX treated 
HL-60 cell proteome). Results are given as the mean values ± S.D. of % volume of spot 
from three independent experiments, * p < 0.05. (B) Influence of MTX on ∆ψm. 
Time-dependent loss of ∆ψm was detected by flow cytometry in MTX treated HL-60 and 




Accumulating evidences suggest that alteration of ATP synthase biogenesis may cause 
two types of isolated defects: qualitative when the enzyme is structurally modified and 
does not function properly, and quantitative when it is present in insufficient amounts. In 
both cases the cellular energy formation is impaired and mitochondria promotes ROS 
generation by the mitochondrial respiratory chain (Houstek et al., 2006; Chen et al., 
2003). Consistent with this notion we showed that SOD2 (useful marker of oxidative 
stress) is significantly down regulated in MTX treated HL-60 cells (Figure 15). To 
validate our previous finding, we analysed the production of the two most abundant ROS 
such as hydrogen peroxide (H2O2) and peroxide nitrite anion (ONOO-) using 
ROS-sensitive fluorescent dye DH-123 (Henderson and Chappell, 1993; Ichiki et al., 
1994; Briviba et al., 1996) in A498 cells. We found that MTX treated A498 cells 
displayed a readily detectable increase in H2O2 and ONOO- levels compared to untreated 
cells in a time dependent manner (Figure 18A&B). This induction in H2O2 and ONOO- 
levels were generated in two distinct phases following MTX treatment. Initially, there 
was a small but consistent increase in H2O2 and ONOO- levels persisted for at least 
72 hours (Figure 18A). This was further associated by substantial two-fold increase in 







Figure 18. Induction of ROS formation in MTX treated A498 cells 
(A) Representative graph shows the kinetics of oxidative stress in 45 µM MTX untreated and treated A498 cells for the indicated time periods. Cells 
were stained with DH-123 for 2 hours, visualized by fluorescence microscopy using specific filter set for rhodamine. The fluorescence was calculated 
(in units) by randomly selected 100 cells. (B) Fluorescence microscopy comparing DH-123 stained untreated and treated A498 cells with 45 µM MTX 
for 72 hours and visualized by using specific filter sets for phase contrast, rhodamine. The obtained figures were merged to observe cell morphology. 




Since 1948, Farber et al. showed that MTX could produce remission in acute leukaemia, 
the folate-dependent enzymes have been the curative regimen in acute lymphocytic 
leukaemia and other leukaemias (Farber, 1950). Various molecular targets have been 
proposed in MTX treated different cell types. However, the complete understanding of 
the molecular basis of drug action of MTX in cancer cells still remains unclear. In this 
study, we investigated a part of the cascade signalling involved in MTX induced 
apoptosis using novel proteomic approaches in acute promyelocytic leukaemia (HL-60) 
and renal epithelial carcinoma (A498) cells. 
6.1 SEQUENTIAL EVENTS OF APOPTOSIS INDUCED IN MTX TREATED 
CANCER CELLS 
Cancer chemotherapeutic drugs initiate cytotoxicity through pro-apoptotic signals 
incoming from various endogenous factors and converge upon pathways mediating 
programmed cell death or apoptosis. MTX, one of the earliest cancer chemotherapeutic 
agents showed cytotoxicity in acute lymphocytic leukemia (Farber, 1950) and other 
cancers (Frei, III et al., 1980). In our experimental model, we showed that MTX also 
causes cytotoxicity in acute promyelocytic cells (HL-60), which was mediated by 
induction of apoptosis. MTX exhibits apoptosis via changes in cellular morphology 
including cell shrinkage and induction in cellular granularity along with biochemical 
event leading to increase translocation of PtdSer at the surface of the plasma membrane 
(Figure 7A&B; Figure 8A). It has been shown in numerous models that these 
morphological and biochemical alterations refers to an apoptosis (Kroemer et al., 2005; 
Martin et al., 1995). Irrespective to these morphological features, mitochondrial 
membrane permeabilization is an universal feature of cell death and is considered as a 
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consequence of charge difference (mitochondrial membrane potential ∆ψm) between the 
mitochondrial matrix and cytosol (Kroemer et al., 1998). Our preliminary results revealed 
that MTX potentially disrupts ∆ψm in HL-60 cells (Figure 17B). Structural irregularities 
due to the differential protein expression of ATP synthase subunits might be a critical 
factor participated in the ∆ψm disruption in MTX treated HL-60 cells (Figure 17A). This 
∆ψm disruption constitutes an early event of apoptosis that precedes cell shrinkage, PtdSer 
translocation and induction of cellular granularity (Figure 17A). Similar findings have 
been obtained in freshly isolated splenocytes stimulated with dexamethasone (Zamzami et 
al., 1995). Following ∆ψm dissipation and mitochondrial membrane permeabilization, an 
increase in mitochondrial matrix volume occurs as a consequence of the massive entry of 
solutes and water. This swelling give rise to a distention and disorganization of the 
mitochondrial membranes resulting in mitochondrial membranes fragmentation (Kroemer 
et al., 1998). In-vivo, such ultrastructural alterations have been previously observed in rat 
liver after exposure to MTX (Al Ali et al., 2005). Taking together, these data argue in 
favor of the possibility that besides morphological alterations, ∆ψm disruption and partial 
lysis of the mitochondrial membranes participated in the apoptotic cascade induced by 
MTX.  
To establish whether other cancer cells also showed MTX cytotoxicity, we investigated 
the effect of MTX on renal epithelial carcinoma (A498) cells. Similar findings i.e. 
induction of PtdSer translocation and ∆ψm disruption were also observed in MTX treated 
renal epithelial carcinoma cells (A498) at a relatively lower rate than in HL-60 cells. This 
is probably due to the well-known differences in the expression of multi-drug resistance 
genes. Over expression of P-glycoprotein, multidrug resistance proteins and decreased 
expression of DNA topoisomerase-II are responsible for expression of the multidrug 
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resistance phenotype in various cancer cells (Naito et al., 2000; Reinecke et al., 2000; 
Nishiyama et al., 1999). 
6.2 MOLECULAR TARGETS AND PATHWAYS INVOLVED IN CELL 
RESPONSE TO MTX 
Due to the wide therapeutic applications of MTX, it is reasonable to speculate that MTX 
may have a number of intracellular protein targets, converging into an apoptotic process. 
The inhibitory action of MTX on NADP-dependent enzymes has been extensively 
investigated by several authors (Babiak et al., 1998; Oliveira et al., 1989). Moreover, a 
number of important observations have been made which reflect towards the additional 
molecular influences of MTX such as inhibition of the ICMT (Winter-Vann et al., 2003) 
and suppression of the NF-κB subunits p65 and p50 (Majumdar and Aggarwal, 2001). 
Despite an increasing knowledge on the molecular targets of MTX in different cell types, 
little is known regarding its apoptotic influences in cancer cells. 
Cysteine labelled differential in-gel electrophoresis combined with mass spectrometry has 
been successfully implemented in the proteomic study of adenoma of Min mice (Kondo et 
al., 2003), hepatocellular carcinoma tissue (Fujii et al., 2005), haematopoietic cells (Evans 
et al., 2004) and in the pathogenesis of the cancer (Kondo et al., 2003; Fujii et al., 2005). 
From a molecular targets point of view, there is currently substantial interest in 
implementing platforms for drug target discovery. Although the proteomic field is in the 
early stages, current proteomic tools such as cysteine labelled differential in-gel 
electrophoresis has the potential to be a major technique in identifying new molecular 
targets of various pharmacological therapeutic agents. In order to characterize the 
molecular targets of MTX induced apoptosis in HL-60 cells, we conducted experiments 
incorporating cysteine labelled differential in-gel electrophoresis. Initial experimental 
analysis revealed a number of differentially expressed proteins in acute promyelocytic 
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leukemia HL-60 cells after exposure to MTX. These proteins were mainly ascribed to the 
ER chaperones, glycolytic enzymes and the mitochondrial transmembrane electron 
transport system (Table 4). Additionally, we observed that several proteasome subunits 
were significantly down regulated in MTX treated HL-60 cells (Figure 13A&B). These 
results provide a broader view of intracellular protein changes accompanying the 
apoptotic effect of MTX in HL-60 cells. 
6.2.1 MTX induced inhibition of NF-κB subunit p65 and proteasome subunits 
correlate with the induction of ER chaperones 
NF-κB, a stress-regulated transcription factor belonging to the Rel family, has a pivotal 
role in the control of various responses. More than 200 physiological, pharmacological 
and chemotherapeutical stimuli are known to activate the NF-κB signalling pathway 
(Tergaonkar, 2006). The NF-κB activation pathways are broadly classified into two 
pathways commonly known as the canonical and non-canonical pathways, depending on 
whether activation involves the IκB degradation or p100 processing (Pomerantz and 
Baltimore, 2002). NF-κB activation and translocation into the nucleus induces the 
transcription of a variety of genes encoding cell adhesion molecules, inflammatory and 
chemotactic cytokines, cytokine receptors, and enzymes that produce inflammatory 
mediators. Accumulating evidences suggested that activation of NF-κB is critical for the 
pathogenesis of leukaemia’s (Baumgartner et al., 2002; Braun et al., 2006; Bueso-Ramos 
et al., 2004; Guzman et al., 2001). Hence, suppression of NF-κB and its associated 
signalling proteins could play an important role in cancer cell death. It has been shown 
that MTX down regulated NF-κB subunits p65 and p50 in Jurkat cells and was implicated 
in cell death (Majumdar and Aggarwal, 2001). Similiarily, MTX inhibits the expression 
of NF-κB subunit p65 in acute promyelocytic leukaemia (HL-60) and renal epithelial 
carcinoma (A498) cells (Figure 16B). The results are in good agreement with what was 
DISCUSSION 
 65
previously reported for MTX treatment in Jurkat cells (Majumdar and Aggarwal, 2001). 
Majumdar and Aggarwal further demonstrated that the suppression of NF-κB subunits 
p65 and p50 was accompanied with the inhibition of IKBα degradation, suppression of 
IKBα phosphorylation, abrogation of IKBα kinase activation, and inhibition of NF-κB 
dependent reporter gene expression (Majumdar and Aggarwal, 2001). Recently, it has 
been shown that p65 subunit of NF-κB knockout (p65-/-) mouse embryonic fibroblasts 
(MEFs) cell line was found to be more susceptible to apoptosis with MTX as compared to 
wild type MEFs (Brengauz-Breitmann et al., 2006). Our findings combined with other 
studies (Brengauz-Breitmann et al., 2006; Majumdar and Aggarwal, 2001) indicate that 
MTX induced apoptosis in various cancer cell types is probably due to blocking NF-κB 
activation. However, until recently how these pathways are integrated to each another is 
still to be determined. 
In order to identify link between inhibition of NF-κB subunit p65 and apoptosis, we 
treated HL-60 cells with MTX and performed cysteine labelled differential in-gel 
electrophoresis combined with mass spectrometry. The important observations of this 
study were the down regulation of structurally (α4, α5 and α7, β3) and regulatory 
proteasome subunits in MTX treated HL-60 cells (Figure 13A&B). Although the main 
catalytic activity of the proteasome is mediated by the β subunits; the α and some 
regulatory subunits are thought to maintain the framework for correct assembly of β 
subunits during biogenesis of the 20S proteasome (Coux et al., 1996). Impairment of α 
and regulatory subunits thereby lead to instability in the 20S proteasome complex 
resulting in impairment in proteasome mediated proteolytic activity (Bulteau et al., 2001; 
Grune et al., 1996; Voges et al., 1999). These evidences emphasize the possible 
involvement of MTX in the integrity of α and regulatory subunits to the normal function 
of proteasome in HL-60 cells. 
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After observing the protein expression of proteasome subunits and its ability to induce 
apoptosis in MTX treated HL-60 cells, we therefore reasoned that lack of proteasomal 
activity might induces an abnormal accumulation of ubiquitinated proteins in ER finally 
causes ER stress. The resulting ER stress is characterized by over expression of ER 
chaperones, also known as unfolded protein response (Ron, 2002; Kaufman, 2002). The 
unfolded protein response includes three mechanisms to handle the vast accumulation of 
unfolded proteins: general transcriptional repression, translational induction of target 
proteins enhancing protein folding and ER-associated degradation pathway to eliminate 
misfolded proteins (Mori, 2000). If the overload of unfolded or misfolded proteins in the 
ER is not resolved, prolonged activation of the unfolded protein response would lead to 
apoptosis (Ron, 2002). In our study MTX activates unfolded protein response in HL-60 
cells by inducing the expression of ER chaperones in a time dependent fashion 
(Figure 16A). Similar findings were also observed in MTX treated renal epithelial 
carcinoma cells (Figure 16A). The effects of MTX on ER chaperones are in accordance 
with earlier findings seen in various cancer cells after treated with proteasome inhibitors 
(Fribley and Wang, 2006; Obeng et al., 2006). These data confirmed the up regulation of 
ER chaperones in MTX treated HL-60 and A498 cells. How these proteins are integrated 
to each another by MTX is yet not clear. 
6.2.2 MTX induced MTETS proteins impairment reveal glycolysis involvement 
Most cancer cells exhibit increased glycolysis and use this metabolic pathway for the 
generation of the ATP as a main source of their energy supply in the absence of oxygen. 
This phenomenon is widely known as the Warburg effect and is considered as one of the 
fundamental metabolic alterations during malignant transformation (Garber, 2006; 
Wallace, 2005). Molecular studies imply several possible mechanisms by which this 
metabolic alteration may evolve during the cancer development. These mechanisms 
DISCUSSION 
 67
include adaptation to hypoxic tumour environment, oncogenic signalling, abnormal 
expression of the metabolic enzymes and mitochondrial defects or malfunction (Kim and 
Dang, 2005). As this metabolic alteration is frequently seen in cancer cells of various 
tissues, targeting the glycolytic pathway may cause apoptosis in malignant cancer cells.  
The effect of MTX on carbohydrate metabolism, in particular glycolytic enzymes have 
been investigated by several authors (Carpentier et al., 1978; Desoize et al., 1978; 
Kaminskas and Nussey, 1978). Some reports demonstrated that MTX enhances the 
intracellular levels of glycolytic enzymes in leukaemia L1210 cells (Desoize et al., 1978 
and Carpentier Y and 1978). Conversely, there was a report suggesting that glycolysis 
was inhibited by MTX at growth inhibitory concentrations. The effect of MTX in cultured 
Ehrich ascites carcinoma cells was severe in low glucose containing media and 
intermediate in high glucose containing media (Kaminskas and Nussey, 1978), suggesting 
the importance of glucose in MTX pharmacological activity. Our proteomic data revealed 
that MTX significantly induces the expression of several glycolytic enzymes in HL-60 
cells (Table 5; Figure 14A&B). This is in concordance with earlier findings where MTX 
potentially enhances glycolysis in leukaemia L1210 cells (Desoize et al., 1978). 
Earlier studies have shown that MTX can affect several aspects of mitochondrial energy 
metabolism, particularly oxidative phosphorylation and induces apoptosis in cancer cells 
(Oliveira et al., 1989; Gosalvez et al., 1974). The inhibitory effect of MTX on several 
mitochondrial enzymes such as 2-oxoglutarate and isocitrate dehydrogenase has been 
reported in the HeLa cells (Caetano et al., 1997). To explore the boarder view of 
mitochondrial-localized changes induced by MTX, we made cysteine labelled differential 
in-gel electrophoresis. We observed that MTX impaired seven additional mitochondrial-
localized proteins (Figure 15) including ATP synthase subunits alpha and beta resulting 
in the ∆ψm collapse as compared to control cancer cells (Figure 17A&B). This study 
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extends the list of mitochondrial-localized proteins affected by MTX in HL-60 cells. With 
the results shown herein, we may speculate that the biological significance resulting from 
the treatment with MTX leads to a reduction of the effectiveness of the MTETS followed 
by high glycolytic flux. The experimental data that indicate these are: Firstly increased 
expression of several enzymes such as ALDOA, GAPDH, PKM2 LDH-A and TPI, that 
will together contribute to increased glycolytic flux. Secondly differentially expression of 
mitochondrial proteins such as ATP5B, ACO2, ATP5A1, UQCRC1, SOD2 and HSPA9B 
besides 2-oxoglutarate, isocitrate and malate dehydrogenases (Caetano et al., 1997) were 
observed when the cancer cells were treated with MTX.  
There are several reports demonstrating that apoptosis caused by MTX may be mediated 
by the production of ROS in Jurkat and HL-60 cells (Phillips et al., 2003; Huang et al., 
2005). Conflicting evidences surround the effect of MTX on the generation of ROS in cell 
line models. One possible mechanism is that MTX decreases the cellular levels of 
glutathione and reduces the effectiveness of the antioxidant enzyme defence system 
(Babiak et al., 1998). In another study, MTX causes ∆ψm disruption and causes apoptosis 
by increased the amount of cytosolic peroxide formation in HL-60 and Jurkat T cells 
(Huang et al., 2005). Our findings support latter study and showed that one of the 
mechanisms of MTX-induced apoptosis may be through a ROS-dependent, mitochondria-




To conclude our findings, we demonstrate for the first time that structural non-
catalytically and regulatory proteasom subunits were down regulated in MTX treated 
HL-60 cells. These evidences suggest the possible involvement of MTX in the integrity of 
α subunits to the normal function of proteasomes. Moreover, MTX down regulates 
NF-κB subunit p65 and induces the expression of the ER chaperones in HL-60 and A498 
cells. Additionally, MTX leads to a reduction of the effectiveness of the MTETS followed 
by high glycolytic flux by altering mitochondrial-localized proteins and glycolytic 





Protein Name:    Calreticulin precursor 
Gene name:    CALR 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P27797 
Mass:     48112 
Score:     89 
Queries matched:   03 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 15   488.2570   974.4994   974.4781   0.0213  0   33   0.027  1   K.GLQTSQDAR.F 
 17   496.7465   991.4784   991.4611   0.0174  0   33   0.026  1   R.QIDNPDYK.G 
 22   565.7599   1129.5052   1129.4927   0.0125  1   23   0.16  1   K.FYGDEEKDK.G 
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Protein Name:    Calmodulin 
Gene name:    CALM2 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P62158 
Mass:     16696 
Score:     187 
Queries matched:   07 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr (expt)   Mr (calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 4   411.2409   820.4672   820.4113   0.0560  0   4   13  1   K.ELGTVMR.S + Oxidation (M) 
 16   478.7747   955.5348   955.4651   0.0698  0   47   0.0007  1   K.EAFSLFDK.D 
 21   547.2792   1092.5438   1092.4571   0.0868  0   42   0.0023  1   K.DTDSEEEIR.E 
 23   633.3598   1264.7050   1264.6047   0.1003  0   43   0.0016  1   K.DGNGYISAAELR.H 
 27   456.9017   1367.6833   1367.5874   0.0958  1   34   0.017  1   K.MKDTDSEEEIR.E + Oxidation (M) 
 34   585.6729   1753.9969   1753.8634   0.1334  1   11   1.9  1   R.VFDKDGNGYISAAELR.H 
 35   923.0095   1844.0044   1843.8839   0.1205  1   6   8  1   K.EAFSLFDKDGDGTITTK.E 
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Protein Name:    78 kDa Glucose regulated protein precursor (Bip protein) 
Gene name:    HSPA5 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P11021 
Mass:     72288 
Score:     989 
Queries matched:   23 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 17   459.7444   917.4742   917.4706   0.0037  0   33   0.022  1   K.VLEDSDLK.K 
 18   491.2532   980.4918   980.4814   0.0104  0   10   3.8  1   K.ETAEAYLGK.K 
 19   493.7692   985.5238   985.5080   0.0159  0   27   0.08  1   R.LTPEEIER.M 
 24   523.7980   1045.5814   1045.5655   0.0159  1   47   0.00099  1   K.VLEDSDLKK.S 
 27   537.7851   1073.5556   1073.5465   0.0091  0   45   0.0013   1   K.ITITNDQNR.L 
 33   596.3239   1190.6332   1190.6295   0.0038  0   52   0.00028  1   K.VYEGERPLTK.D 
 34   609.3318   1216.6490   1216.6234   0.0257  0   32  0.024   1   K.DAGTIAGLNVMR.I 
 35   614.8340   1227.6534   1227.6207   0.0327  0   48   0.00065  1   R.VEIIANDQGNR.I 
 36   617.3259   1232.6372   1232.6183   0.0190  0   41   0.0031   1   K.DAGTIAGLNVMR.I + Oxidation (M) 
 45   658.8332   1315.6518   1315.6295   0.0223  0   76   1.1e-06   1   R.NELESYAYSLK.N 
 51   699.4104   1396.8062   1396.7813   0.0250  0   62   1.6e-05  1   K.ELEEIVQPIISK.L 
 52   715.8542   1429.6938   1429.6837   0.0101  0   48   0.00064 1   R.TWNDPSVQQDIK.F 
 56   730.8893   1459.7640   1459.7518   0.0123  0   47   0.0008  1   K.SDIDEIVLVGGSTR.I 
 61   768.9067   1535.7988   1535.7905   0.0084  0   49   0.000461   K.TFAPEEISAMVLTK.M 
 62   776.9102   1551.8058   1551.7854   0.0204  0   44  0.0012  1   K.TFAPEEISAMVLTK.M + Oxidation (M) 
 63   783.8982   1565.7818   1565.7725   0.0093  0   50   0.00036 1   R.ITPSYVAFTPEGER.L 
 64   794.8961   1587.7776   1587.8467   -0.0691  1   4  15 1   K.KSDIDEIVLVGGSTR.I 
 65   530.2718   1587.7936   1587.8467   -0.0532 1   20   0.36  1   K.KSDIDEIVLVGGSTR.I 
 70   830.4575   1658.9004   1658.8879   0.0126  0   93   1.5e-08  1   R.IINEPTAAAIAYGLDK.R 
 71   839.4112   1676.8078   1676.8005   0.0073  0   92   2.2e-08  1   K.NQLTSNPENTVFDAK.R 
 79   918.9685   1835.9224   1835.9265   -0.0040 0   103   1.9e-09  1   K.SQIFSTASDNQPTVTIK.V 
 82   629.9977   1886.9713   1886.9638   0.0074  0   26   0.074  1   K.VTHAVVTVPAYFNDAQR.Q 
 84   1088.4921   2174.9696   2174.9855   -0.0158 1   23   0.14  1   K.LYGSAGPPPTGEEDTAEKDEL 
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 Protein Name:   Proteasome subunit alpha type 4 
Gene name:    PSMA4 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P25789 
Mass:     29465 
Score:     236 
Queries matched:   09 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 15   429.7823   857.5500   857.4858   0.0643  0   6   7.9  5   K.EVEQLIK.K 
 24   451.7991   901.5836   901.5233   0.0604  0   37   0.0036  1   K.VEIATLTR.E 
 29   500.2776   998.5406   998.4821   0.0585  0   40   0.0036  1   K.QAYTQFGGK.R 
 30   504.3059   1006.5972   1006.5083   0.0889  0   10  2.9  1   R.TTIFSPEGR.L 
 31   504.3088   1006.6030   1006.5083   0.0947  0   30   0.026  1   R.TTIFSPEGR.L 
 41   557.8675   1113.7204   1113.6393   0.0811  1   3   7.2  1   K.QKEVEQLIK.K 
 46   613.8656   1225.7166   1225.6230   0.0936  0   66   7e-06  1   K.LLDEVFFSEK.I 
 56   477.6494   1429.9264   1429.8140   0.1124  1   3   2.7  1   K.LSAEKVEIATLTR.E 
 61   804.4542   1606.8938   1606.7807   0.1132  0   53   0.00015 1   K.ATCIGNNSAAAVSMLK.Q + Carbamidomethyl (C) 
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Protein Name:    Proteasome subunit alpha type 5 
Gene name:    PSMA5 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P28066 
Mass:     26394 
Score:     274 
Queries matched:   08 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 14   494.7848   987.5550   987.5124   0.0427  0   40   0.0039  1   K.EELEEVIK.D 
 17   532.2729   1062.5312   1062.5094   0.0219  0   25   0.16  1   R.GVNTFSPEGR.L 
 22   608.8397   1215.6648   1215.6234   0.0415  1   25   0.12  1   K.EELEEVIKDI 
 28   712.4234   1422.8322   1422.7758   0.0564  0   65   7.9e-06  1   R.LFQVEYAIEAIK.L 
 29   716.3946   1430.7746   1430.7327   0.0420  0   37   0.0067  1   R.ITSPLMEPSSIEK.I 
 30   724.3927   1446.7708   1446.7276   0.0433  0   30  0.034  1   R.ITSPLMEPSSIEK.I + Oxidation (M) 
 31   981.5009   1960.9872   1960.9490   0.0383  0   82   1.9e-07  1   R.AIGSASEGAQSSLQEVYHK.S 
 32   654.6804   1961.0194   1960.9490   0.0704  0   5  9.1  1   R.AIGSASEGAQSSLQEVYHK.S 
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Protein Name:    Proteasome subunit alpha type 7 
Gene name:    PSMA7 
Taxonomy:    Homo sapiens 
Swiss Prot No:   o14818 
Mass:     27870 
Score:     255 
Queries matched:   06 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 6   426.2604   850.5062   850.4436   0.0627  0   17   0.46  1   K.YVAEIEK.E 
 16   486.3261   970.6376   970.5698   0.0678  0   43   0.00084  1   R.DIVVLGVEK.K 
 21   542.8480   1083.6814   1083.5811   0.1003  0   42   0.0011  1   K.ILNPEEIEK.Y 
 22   550.8622   1099.7098   1099.6237   0.0862  0   46   0.00039  1   K.ALLEVVQSGGK.N 
 27   817.9969   1633.9792   1633.8563   0.1230  0   46   0.00043  1   R.LTVEDPVTVEYITR.Y 
 30   870.9689   1739.9232   1739.8101   0.1131  0   63   1.7e-05  1   K.NYTDEAIETDDLTIK.L 
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Protein Name:    Proteasome subunit beta type 3 
Gene name:    PSMB3 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P49720 
Mass:     22933 
Score:     215 
Queries matched:   07 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 14   446.7784   891.5422   891.5065   0.0357  0   10   2.5  1   R.LNLYELK.E 
 19   495.2643   988.5140   988.4760   0.0381  0   32   0.03  1   K.NCVAIAADR.R + Carbamidomethyl (C) 
 25   784.4592   1566.9038   1566.8439   0.0600  0   42   0.0016  1   R.DAVSGMGVIVHIIEK.D 
 26   815.4222   1628.8298   1628.7868   0.0430  0   23   0.18  1   R.FGIQAQMVTTDFQK.I + Oxidation (M) 
 27   883.9803   1765.9460   1765.8926   0.0534  0   50   0.00032  1   R.FGPYYTEPVIAGLDPK.T 
 30   630.3754   1888.1044   1888.0417   0.0626  0   15  0.55  1   R.LYIGLAGLATDVQTVAQR.L 
 31   945.0665   1888.1184   1888.0417   0.0767  0   58   2.3e-05  1   R.LYIGLAGLATDVQTVAQR.L 
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Protein Name:    26S Protease regulatory subunit 8 (p45/SUG) 
Gene name:    PSMC5 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P62195 
Mass:     45597 
Score:     300 
Queries matched:   09 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr (expt)   Mr (calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 3   401.2498   800.4850   800.4068   0.0782  0   4   17  1   R.QYYLSK.I 
 15   463.8220   925.6294   925.5484   0.0811  0   20   0.056  1   K.EVIELPVK.H 
 17   473.8017   945.5888   945.5131   0.0758  0   47   0.00045  1   R.VSGSELVQK.F 
 20   489.2747   976.5348   976.4614   0.0735  0   7   10  1   R.NDSYTLHK.I 
 26   579.8720   1157.7294   1157.6444   0.0851  0   30   0.02  1   K.GVLLYGPPGTGK.T 
 28   645.8521   1289.6896   1289.5847   0.1049  0   67   7.4e-06  1   R.LEGGSGGDSEVQR.T 
 29   649.8703   1297.7260   1297.6302   0.0958  0   14   1.1  1   K.IEFPPPNEEAR.L 
 30   657.4189   1312.8232   1312.7238   0.0995  0   59   1.8e-05  1   K.IEELQLIVNDK.S 
 34   715.8962   1429.7778   1429.6620   0.1159  0   53   0.00016  1   K.NIDINDVTPNCR.V + Carbamidomethyl (C) 
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Protein Name:    26S Protease regulatory subunit s10B (Proteasome subunit p42) 
Gene name:    PSMC6 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P62333 
Mass:     44145 
Score:     362 
Queries matched:   10 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 6   418.7894   835.5642   835.4916   0.0727  0   4   1.4  1   K.IHAGPITK.H 
 15   467.3053   932.5960   932.5178   0.0782  0   47   0.00031  1   K.VVSSSIVDK.Y 
 19   485.2583   968.5020   968.4199   0.0821  0   50   0.0004  1   R.FSEGTSADR.E 
 21   504.7979   1007.5812   1007.5036   0.0777  1   26   0.073  1   R.DKALQDYR.K 
 25   582.8313   1163.6480   1163.5571   0.0910  0   63   1.7e-05  1   K.LSDGFNGADLR.N 
 27   610.3530   1218.6914   1218.6066   0.0848  0   31   0.027  1   K.GCLLYGPPGTGK.T + Carbamidomethyl (C) 
 29   637.3812   1272.7478   1272.6350   0.1129  0   31   0.021  1   K.HGEIDYEAIVK.L 
 34   683.3949   1364.7752   1364.6758   0.0995  0   61   2.7e-05  1   R.AVASQLDCNFLK.V + Carbamidomethyl (C) 
 35   692.8710   1383.7274   1383.6275   0.1000  0   17   0.85  1   R.NVCTEAGMFAIR.A + Carbamidomethyl (C) 
 41 899.5498   1797.0850   1796.9672   0.1179  0   33   0.0057  1   R.EVIELPLTNPELFQR.V 
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Protein Name:    Aconitate hydratase, mitochondrial precursor 
Gene name:    ACO2 
Taxonomy:    Homo sapiens 
Swiss Prot No:   Q99798 
Mass:     85372 
Score:     177 
Queries matched:   08 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 4   400.7866   799.5586   799.5167   0.0420  0   1   12  1   K.VAGILTVK.G 
 17   461.7712   921.5278   921.4668   0.0611  0   20   0.31  1   R.EHAALEPR.H 
 18   468.2798   934.5450   934.4872   0.0578  0   22   0.2  1   R.DGYAQILR.D 
 23   493.2851   984.5556   984.5029   0.0528  0   15   1  1   K.EGWPLDIR.V 
 24   501.8082   1001.6018   1001.5545   0.0473  0   30   0.032  1   K.DFTPGKPLK.C 
 47   732.4156   1462.8166   1462.7416   0.0751  0   25   0.087  1   K.SQFTITPGSEQIR.A 
 50   533.9355   1598.7847   1598.7285   0.0562  0   23   0.2  1   K.DSSGQHVDVSPTSQR.L 
 51   801.4456   1600.8766   1600.7845   0.0922  0   40   0.003  1   R.NAVTQEFGPVPDTAR.Y 
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Protein Name:    ATP synthase subunit beta, mitochondrial precursor 
Gene name:    ATP5B 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P06576 
Mass:     56525 
Score:     677 
Queries matched:   19 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 9   450.2942   898.5738   898.5123   0.0615  0   42   0.0012  1   K.VLDSGAPIK.I 
 11   488.3246   974.6346   974.5548   0.0798  0   29   0.016  1   K.IGLFGGAGVGK.T 
 14   519.8387   1037.6628   1037.5869   0.0759  0   44   0.00037  1   K.IPVGPETLGR.I 
 20   544.8633   1087.7120   1087.6277   0.0843  0   46   0.00021  1   K.VVDLLAPYAK.G 
 29   631.8668   1261.7190   1261.6336   0.0855  0   41   0.0029  1   R.TIAMDGTEGLVR.G 
 30   639.8633   1277.7120   1277.6285   0.0835  0   37  0.0066  1   R.TIAMDGTEGLVR.G + Oxidation (M) 
 35   693.4084   1384.8022   1384.7020   0.1003  0   37   0.0054  1   R.IMNVIGEPIDER.G 
 37   701.4039   1400.7932   1400.6969   0.0963  0   35  0.0091  1   R.IMNVIGEPIDER.G + Oxidation (M) 
 38   469.6003   1405.7791   1405.6738   0.1053  0   21   0.25  1   K.AHGGYSVFAGVGER.T 
 39   718.4271   1434.8396   1434.7466   0.0930  0   95   8.1e-09  1   R.FTQAGSEVSALLGR.I 
 41   720.4430   1438.8714   1438.7820   0.0895  0   87   2.9e-08  1   R.VALTGLTVAEYFR.D 
 43   729.4686   1456.9226   1456.8323   0.0904  0   40  0.00096  1   K.TVLIMELINNVAK.A 
 46   737.4821   1472.9496   1472.8272   0.1225  0   50   6.3e-05  1   K.TVLIMELINNVAK.A + Oxidation (M) 
 57   801.4634   1600.9122   1600.8031   0.1092  0   44  0.0012  1   K.VALVYGQMNEPPGAR.A 
 60   809.4618   1616.9090   1616.7980   0.1110  0   47   0.00056  1   K.VALVYGQMNEPPGAR.A + Oxidation (M) 
 62   826.0221   1650.0296   1649.9100   0.1196  0   52   4.6e-05  1   R.LVLEVAQHLGESTVR.T 
 63   551.0172   1650.0298   1649.9100   0.1198  0   36  0.0023  1   R.LVLEVAQHLGESTVR.T 
 76   994.5826   1987.1506   1987.0262   0.1245  0   46   0.00043  1   R.AIAELGIYPAVDPLDSTSR.I 
 85   1149.6022   2297.1898   2297.0667   0.1231  0   39   0.0033  1   R.IPSAVGYQPTLATDMGTMQER.I + 2 Oxidation (M) 
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Protein Name:    ATP synthase subunit alpha, mitochondrial precursor 
Gene name:    ATP5A1 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P25705 
Mass:     59714 
Score:     141 
Queries matched:   07 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 6   423.2734   844.5322   844.5018   0.0305  0   14   1.2  1   R.STVAQLVK.R 
 14   438.7756   875.5366   875.4899   0.0468  0   20   0.3  1   R.QMSLLLR.R + Oxidation (M) 
 20   500.8151   999.6156   999.5712   0.0444  0   6   6.9  1   R.VLSIGDGIAR.V 
 22   513.8162   1025.6178   1025.5869   0.0309  0   22   0.13  1   K.AVDSLVPIGR.G 
 25   586.3336   1170.6526   1170.6244   0.0283  0   38   0.0062  1   R.VVDALGNAIDGK.G 
 27   658.8932   1315.7718   1315.7347   0.0371  0   19   0.39  1   K.TSIAIDTIINQK.R 
 29   812.9684   1623.9222   1623.8831   0.0391  0   23   0.13  1   R.TGAIVDVPVGEELLGR.V 
APPENDIX 
 82
Protein Name:    Fructose-bisphosphate aldolase A 
Gene name:    ALDOA 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P04075 
Mass:     39264 
Score:     242 
Queries matched:   08 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 3   401.2808   800.5470   800.4756   0.0715  0   12   0.81  1   R.ALQASALK.A 
 13   464.2510   926.4874   926.4167   0.0707  0   4   13  1   R.CQYVTEK.V + Carbamidomethyl (C) 
 20   522.8375   1043.6604   1043.5611   0.0993  0   39   0.0025  1   R.QLLLTADDR.V 
 24   547.3272   1092.6398   1092.5563   0.0835  1   44   0.0011  1   K.AAQEEYVKR.A 
 27   566.8320   1131.6494   1131.5706   0.0788  0   64   1.3e-05  1   R.ALANSLACQGK.Y + Carbamidomethyl (C) 
 34   666.9040   1331.7934   1331.6932   0.1002  0   47   0.00054  1   K.GILAADESTGSIAK.R 
 37   717.9208   1433.8270   1433.7191   0.1080  0   32   0.015  1   -.PYQYPALTPEQK.K 
 40   549.6471   1645.9195   1645.8019   0.1175  1   2   18  1   R.LQSIGTENTEENRR.F 
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Protein Name:    Glyceraldehyde-3-phosphate dehydrogenase 
Gene name:    GAPDH 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P04406 
Mass:     35899 
Score:     536 
Queries matched:   24 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 6   403.2310   804.4474   804.4242   0.0233  0   33   0.022  1   K.VGVNGFGR.I 
  7   403.2445   804.4744   804.4242   0.0503  0   8  5.1  2   K.VGVNGFGR.I 
 8   403.2482   804.4818   804.4242   0.0577  0   25  0.097  1   K.VGVNGFGR.I 
 10   403.2496   804.4846   804.4242   0.0605  0   19  0.4  1   K.VGVNGFGR.I 
 11   403.2508   804.4870   804.4242   0.0629  0   14  1.1  1   K.VGVNGFGR.I 
  12   403.2525   804.4904   804.4242   0.0663  0   5  9.1  2   K.VGVNGFGR.I 
 18   415.2531   828.4916   828.4341   0.0576  0   17   0.83  1   K.QASEGPLK.G 
 25   435.2781   868.5416   868.5018   0.0399  0   32   0.0082  1   K.VIPELNGK.L 
 50   601.3527   1200.6908   1200.5995   0.0914  0   8   5.2  1   R.VVDLMAHMASK.E 
 63   706.4012   1410.7878   1410.7830   0.0048  0   57   5.4e-05  1   R.GALQNIIPASTGAAK.A 
 64   706.4482   1410.8818   1410.7830   0.0988  0   22  0.07  1   R.GALQNIIPASTGAAK.A 
 65   706.4482   1410.8818   1410.7830   0.0988  0   28  0.021  1   R.GALQNIIPASTGAAK.A 
 66   706.4504   1410.8862   1410.7830   0.1032  0   27  0.023  1   R.GALQNIIPASTGAAK.A 
 67   706.4508   1410.8870   1410.7830   0.1040  0   24  0.048  1   R.GALQNIIPASTGAAK.A 
 68   706.4528   1410.8910   1410.7830   0.1080  0   32  0.0064  1   R.GALQNIIPASTGAAK.A 
 69   706.4571   1410.8996   1410.7830   0.1166  0   5  3.3  1   R.GALQNIIPASTGAAK.A 
 77   765.9047   1529.7948   1529.7871   0.0077  0   92   2.1e-08  1   R.VPTANVSVVDLTCR.L + Carbamidomethyl (C) 
 78   765.9556   1529.8966   1529.7871   0.1095  0   53  0.00013  1   R.VPTANVSVVDLTCR.L + Carbamidomethyl (C) 
 88   807.5146   1613.0146   1612.8936   0.1210  0   58   1.2e-05  1   K.LVINGNPITIFQER.D 
 96   882.4482   1762.8818   1762.7950   0.0868  0   71   3.6e-06  1   K.LISWYDNEFGYSNR.V 
 97   882.4657   1762.9168   1762.7950   0.1218  0   55  0.00012  1   K.LISWYDNEFGYSNR.V 
 98   882.4754   1762.9362   1762.7950   0.1412  0   62  2.4e-05  1   K.LISWYDNEFGYSNR.V 
 108   917.5035   1832.9924   1832.9124   0.0800  0   135   8.8e-13  1   K.IISNASCTTNCLAPLAK.V + 2 Carbamidomethyl (C) 
 128   1139.0968   2276.1790   2276.0306   0.1484  0   32   0.017  1   K.WGDAGAEYVVESTGVFTTMEK.A 
APPENDIX 
 84
Protein Name:    L-lactate dehydrogenase A chain 
Gene name:    LDH-A 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P00338 
Mass:     36534 
Score:     349 
Queries matched:   08 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 14   457.3351   912.6556   912.5756   0.0800  0   38   0.00067  1   K.LVIITAGAR.Q 
 15   465.3272   928.6398   928.5745   0.0653  0   8   0.99  1   K.FIIPNVVK.Y 
 19   506.2862   1010.5578   1010.4669   0.0910  0   49   0.00045  1   K.DYNVTANSK.L 
 22   559.8436   1117.6726   1117.5768   0.0959  0   33   0.012  1   K.SADTLWGIQK.E 
 23   560.3669   1118.7192   1118.6335   0.0857  0   31   0.0083  1   K.DQLIYNLLK.E 
 24   567.8273   1133.6400   1133.5564   0.0837  0   56   9.3e-05  1   K.VTLTSEEEAR.L 
 26   624.8496   1247.6846   1247.5928   0.0919  0   66   8.6e-06  1   R.VIGSGCNLDSAR.F + Carbamidomethyl (C) 
 27   632.8881   1263.7616   1263.6710   0.0906  0   69   2.2e-06  1   K.QVVESAYEVIK.L 
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Protein Name:    Pyruvate dehydrogenase E1 component subunit beta, mitochondrial precursor 
Gene name:    PDHB 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P11177 
Mass:     39194 
Score:     392 
Queries matched:   11 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
  1   410.2821   818.5496   818.4902   0.0595  0   8   1.2  2   K.DIIFAIK.K 
 10   451.8052   901.5958   901.5273   0.0686  0   16   0.33  1   K.DFLIPIGK.A 
 22   616.3432   1230.6718   1230.5880   0.0838  0   29   0.05  1   K.VVSPWNSEDAK.G 
 24   628.3926   1254.7706   1254.6819   0.0887  0   47   0.00034  1   K.ILEDNSIPQVK.D 
 25   632.8622   1263.7098   1263.6169   0.0930  0   24   0.14  1   R.VTGADVPMPYAK.I + Oxidation (M) 
 27   676.3417   1350.6688   1350.5907   0.0781  0   32   0.021  1   K.EGVECEVINMR.T + Carbamidomethyl (C); Oxidation (M) 
 29   768.3867   1534.7588   1534.6569   0.1019  0   36   0.0087  1   R.DAINQGMDEELER.D + Oxidation (M) 
 38   882.4966   1762.9786   1762.8712   0.1075  0   86   7.6e-08  1   R.IMEGPAFNFLDAPAVR.V + Oxidation (M) 
 40   901.5106   1801.0066   1800.8933   0.1133  0   66   6.8e-06  1   K.VFLLGEEVAQYDGAYK.V 
 41   922.5328   1843.0510   1842.9338   0.1173  0   43   0.0013  1   K.TYYMSGGLQPVPIVFR.G + Oxidation (M) 
 42   634.0153   1899.0241   1898.8787   0.1453  0   5   9  1   R.TIRPMDMETIEASVMK.T + 3 Oxidation (M) 
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Protein Name:    Pyruvate kinase, isoenzymes M1/M2 E1 component subunit beta, mitochondrial precursor 
Gene name:    PKM2 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P14618 
Mass:     57769 
Score:     690 
Queries matched:   15 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 12   442.7211   883.4276   883.4698   -0.0421  0   23   0.16  1   R.MQHLIAR.E + Oxidation (M) 
 13   456.7120   911.4094   911.4461   -0.0366  0   50   0.00027  1   K.ASDVHEVR.K 
 14   477.2236   952.4326   952.4726   -0.0399  0   39   0.0047  1   K.IENHEGVR.R 
 16   495.7355   989.4564   989.5029   -0.0464  0   3   21  1   K.GSGTAEVELK.K 
 18   510.2402   1018.4658   1018.5083   -0.0425  0   1   34  1   K.GDYPLEAVR.M 
  19   520.7584   1039.5022   1039.5410   -0.0388  1   1   28  2   K.ASDVHEVRK.V 
 22   559.7850   1117.5554   1117.5978   -0.0424  1   62   2.7e-05  1   K.GSGTAEVELKK.G 
 23   571.2844   1140.5542   1140.6026   -0.0484  0   28   0.063  1   R.GDLGIEIPAEK.V 
 25   597.3013   1192.5880   1192.6373   -0.0492  1   45   0.0014  1   R.SVETLKEMIK.S + Oxidation (M) 
 26   599.3040   1196.5934   1196.6401   -0.0466  0   55   0.00013  1   R.LDIDSPPITAR.N 
 27   607.2697   1212.5248   1212.5696   -0.0448  0   54   0.00012  1   K.ITLDNAYMEK.C + Oxidation (M) 
 35   680.3224   1358.6302   1358.6976   -0.0674  0   60   4e-05  1   R.NTGIICTIGPASR.S + Carbamidomethyl (C) 
 38   731.8821   1461.7496   1461.8078   -0.0582  0   78   5.6e-07  1   K.IYVDDGLISLQVK.Q 
 39   734.8108   1467.6070   1467.6704   -0.0633  0   46   0.00055  1   K.CDENILWLDYK.N + Carbamidomethyl (C) 
 41   818.9216   1635.8286   1635.8831   -0.0545  0   60   3.8e-05  1   K.GVNLPGAAVDLPAVSEK.D 
 42   821.8513   1641.6880   1641.7634   -0.0754  0   61   1.9e-05  1   K.DPVQEAWAEDVDLR.V 
 44   882.9604   1763.9062   1763.9781   -0.0718  1   29   0.043  1   K.KGVNLPGAAVDLPAVSEK.D 




Protein Name:    Stress-70 protein, mitochondria precursor (75 glucose regulated protein) 
Gene name:    HSPA9B 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P38646 
Mass:     73635 
Score:     831 
Queries matched:   19 
 
Summarized table of matched peptides: 
 
Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 10   431.7600   861.5054   861.4443   0.0611  0   34   0.017  1   R.ETGVDLTK.D 
 17   479.7805   957.5464   957.4879   0.0585  0   45   0.0011  1   K.VLENAEGAR.T 
 18   490.2579   978.5012   978.4328   0.0685  0   3   22  1   K.DDIENMVK.N + Oxidation (M) 
 20   497.2690   992.5234   992.4451   0.0784  0   10   4.7  1   R.YDDPEVQK.D 
 23   575.3174   1148.6202   1148.5462   0.0741  1   26   0.098  1   R.RYDDPEVQK.D 
 25   616.3730   1230.7314   1230.6568   0.0747  0   85   8.3e-08  1   R.QAASSLQQASLK.L 
 26   621.8849   1241.7552   1241.6727   0.0825  0   46   0.00053  1   K.DAGQISGLNVLR.V 
 27   645.8797   1289.7448   1289.6728   0.0721  0   56   7.9e-05  1   K.VQQTVQDLFGR.A 
 31   447.9034   1340.6884   1340.6109   0.0775  0   1   32  1   R.ASNGDAWVEAHGK.L 
 32   681.4254   1360.8362   1360.7350   0.1012  0   37   0.0026  1   R.AQFEGIVTDLIR.R 
 33   725.9097   1449.8048   1449.7099   0.0949  0   73   1.5e-06  1   R.TTPSVVAFTADGER.L 
 34   731.9410   1461.8674   1461.7497   0.1178  0   24   0.087  1   K.SDIGEVILVGGMTR.M + Oxidation (M) 
 35   737.4470   1472.8794   1472.7834   0.0960  0   52   0.00012  1   R.EQQIVIQSSGGLSK.D 
 36   784.9376   1567.8606   1567.7630   0.0976  0   53   0.00015  1   R.QAVTNPNNTFYATK.R 
 37   536.9615   1607.8627   1607.7613   0.1014  1   2   22  1   K.MKETAENYLGHTAK.N + Oxidation (M) 
 39   823.4917   1644.9688   1644.8722   0.0966  0   97   3.7e-09  1   R.VINEPTAAALAYGLDK.S 
 40   847.9773   1693.9400   1693.8423   0.0977  0   24   0.11  1   K.NAVITVPAYFNDSQR.Q 
 42   905.0099   1808.0052   1807.8952   0.1101  0   92   1.7e-08  1   K.SQVFSTAADGQTQVEIK.V 
 45   1028.5375   2055.0604   2054.9545   0.1060  0   71   2.2e-06  1   K.STNGDTFLGGEDFDQALLR.H 
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Protein Name:    Superoxide dismutase (Mn) 
Gene name:    SOD2 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P04179 
Mass:     24707 
Score:     34 
Queries matched:   01 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 16   712.9363   1423.8580   1423.8034   0.0546  0   34   0.0059  1   K.GDVTAQIALQPALK.F 
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Protein Name:    Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial precursor 
Gene name:    UQCRC1 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P31930 
Mass:     52612 
Score:     135 
Queries matched:   06 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 1   405.2478   808.4810   808.4079   0.0732  0   15   0.69  1   R.FTGSEIR.H 
 2   405.2639   808.5132   808.4443   0.0690  0   10   1.4  1   R.SLLTYGR.R 
 13   486.3088   970.6030   970.5195   0.0835  0   15   0.84  1   K.NRPGSALEK.E 
 16   529.8335   1057.6524   1057.5767   0.0757  0   32   0.017  1   R.IAEVDASVVR.E 
 18   662.3639   1322.7132   1322.6136   0.0996  0   60   3.8e-05  1   R.LCTSATESEVAR.G + Carbamidomethyl (C) 
 21   560.9692   1679.8858   1679.7573   0.1285  0   6   9.4  1   K.EVESMGAHLNAYSTR.E + Oxidation (M) 
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Protein Name:    Short chain 3-hydroxy-CoA dehydrogenase mitochondrial precursor 
Gene name:    HADHSC 
Taxonomy:    Homo sapiens 
Swiss Prot No:   Q16836 
Mass:     34256 
Score:     121 
Queries matched:   04 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 15   447.7512   893.4878   893.4130   0.0748  0   35   0.014  1   K.AGDEFVEK.T 
 16   466.3039   930.5932   930.5134   0.0799  1   7   4.1  1   K.KGIEESLR.K 
 19   509.8076   1017.6006   1017.5243   0.0763  0   33   0.015  1   K.DTPGFIVNR.L 
 22   586.8350   1171.6554   1171.5761   0.0794  0   48   0.00055  1   K.TFESLVDFSK.A 
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Protein Name:    Alpha-2-HS-glycoprotein precursor (Fetuin-A) 
Gene name:    AHSG 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P02765 
Mass:     39300 
Score:     149 
Queries matched:   04 
 
Summarized table of matched peptides: 
 
Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 11   424.2310   846.4474   846.4269   0.0205  0   17   1  1   K.CNLLAEK.Q + Carbamidomethyl (C) 
 32   669.2881   1336.5616   1336.5201   0.0415  0   65   9.4e-06  1   K.CDSSPDSAEDVR.K + Carbamidomethyl (C) 
 36   489.2238   1464.6496   1464.6151   0.0345  1   67   5.7e-06  1   K.CDSSPDSAEDVRK.V + Carbamidomethyl (C) 
 37   733.3438   1464.6730   1464.6151   0.0580  1   16  0.94  1   K.CDSSPDSAEDVRK.V + Carbamidomethyl (C) 
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 Protein Name:   Ran-specific GTPase-activating protein (Ran-binding protein 1) 
Gene name:    RANBP1 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P43487 
Mass:     23296 
Score:     283 
Queries matched:   07 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 16   485.2460   968.4774   968.4385   0.0389  1   14   1.5  1   K.TKFEECR.K + Carbamidomethyl (C) 
 20   517.7781 1033.5416   1033.5192   0.0224  0   45   0.0015  1   R.FLNAENAQK.F 
 21   517.7903   1033.5660   1033.5192   0.0468  0   8   6.5  1   R.FLNAENAQK.F 
 25   593.8829   1185.7512   1185.6968   0.0544  1   24   0:063  1   K.VAEKLEALSVK.E 
 34 668.3370 1334.6594 1334.6142 0.0452 0 87 8.5e-08 1 R.FASENDLPEWK.E 
 40 691.3442 1380.6738 1380.6296 0.0442 0 99 4.5e-09 1 K.TLEEDEEELFK.M 
 56 984.2092 3932.8077 3932.7096 0.0981 0 14 0.51 1           K.DTHEDHDTSTENTDESNHDPQFEPIVSLPEQEIK.T 
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Protein Name:    Rho-GDP-dissociation inhibitor 2 
Gene name:    ARHGDIB 
Taxonomy:    Homo sapiens 
Swiss Prot No:   P52566 
Mass:     22843 
Score:     121 
Queries matched:   04 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 5   428.2708   854.5270   854.4974   0.0297  0   41   0.0012  1   K.APNVVVTR.L 
 11   483.7654   965.5162   965.4719   0.0444  0   15   1.1  1   K.YVQHTYR.T 
 15   542.8330   1083.6514   1083.6077   0.0438  0   4   10  1   K.LNYKPPPQK.S 
 17   656.3851   1310.7556   1310.7081   0.0475  0   60   2.5e-05  1   K.TLLGDGPVVTDPK.A 
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Protein Name:    Far upstream element-binding protein 1 
Gene name:    FUBP1 
Taxonomy:    Homo sapiens 
Swiss Prot No:   Q96AE4 
Mass:     67431 
Score:     268 
Queries matched:   09 
 
Summarized table of matched peptides: 
 
 Query   Observed   Mr(expt)   Mr(calc)    Delta  Miss  Score  Expect  Rank  Peptide 
 
 13   436.7511   871.4876   871.4511   0.0365  0   6   12  1   K.IQNDAGVR.I 
 18   479.3060   956.5974   956.5542   0.0432  0   39   0.0029  1   R.LLDQIVEK.G 
 20   509.7973   1017.5800   1017.5528   0.0272  0   11   3.2  1   K.EMVLELIR.D + Oxidation (M) 
 22   534.3174   1066.6202   1066.5771   0.0432  0   49   0.00036  1   R.IAQITGPPDR.C 
 23   574.8113   1147.6080   1147.5622   0.0459  0   48   0.00072  1   R.GTPQQIDYAR.Q 
 24   597.8048   1193.5950   1193.5499   0.0452  0   3   20  1   R.NPPPNADPNMK.L 
 28   668.8921   1335.7696   1335.7146   0.0550  0   63   1.2e-05  1   R.IGGNEGIDVPIPR.F 
 29   676.8860   1351.7574   1351.7095   0.0479  0   39   0.0038  1   K.IQIAPDSGGLPER.S 
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